<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01346592</url>
  </required_header>
  <id_info>
    <org_study_id>V70_29</org_study_id>
    <nct_id>NCT01346592</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, and Immunogenicity of the Adjuvanted Trivalent Subunit Influenza Vaccine and the Non-Adjuvanted Trivalent Subunit Influenza Vaccine Compared to the Non-Adjuvanted Trivalent Split Influenza Vaccine in Children 6 to &lt; 72 Months of Age</brief_title>
  <official_title>A Phase III, Observer-Blind, Randomized, Multi-center Study to Evaluate the Safety, Tolerability, and Immunogenicity of Fluad and Agriflu Compared to the Non-adjuvanted Trivalent Influenza Vaccine Fluzone in Children 6 to &lt; 72 Months of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Vaccines</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This Study Aims to Evaluate the Safety, Tolerability, and Immunogenicity of the Adjuvanted
      Trivalent Subunit Influenza Vaccine and the Non-Adjuvanted Trivalent Subunit Influenza
      Vaccine Compared to the Non-Adjuvanted Trivalent Split Influenza Vaccine in Children 6 to &lt;
      72 Months of Age.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of Antibody Responses of aTIV With TIV and Comparator TIV in Terms of Geometric Mean Titers (GMTs) Against Homologous Strains</measure>
    <time_frame>Day 1, Day 50</time_frame>
    <description>The non-inferiority of Hemagglutination Inhibition (HI) antibody responses of aTIV compared to TIV and comparator TIV assessed in terms of post vaccination GMTs at three weeks after last vaccination against the three homologous vaccine strains.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparison of Antibody Responses of aTIV With TIV and Comparator TIV in Terms of Percentage of Subjects Achieving Seroconversion or ≥4-fold Increase in HI Titers Against Homologous Strains</measure>
    <time_frame>Day 50</time_frame>
    <description>The non-inferiority of HI antibody responses of aTIV compared to TIV and comparator TIV assessed in terms of percentage of subjects achieving seroconversion or ≥4-fold increase in HI titers at three weeks after last vaccination against the three homologous vaccine strains.
Seroconversion defined as prevaccination HI titer &lt;10 and postvaccination HI titer ≥40 or at least a 4-fold increase in HI titers from prevaccination HI titer ≥10.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparison of Antibody Responses of TIV Versus Comparator TIV in Terms of Geometric Mean Titers (GMTs) Against Homologous Strains (6 to &lt;36 Months)</measure>
    <time_frame>Day 1, Day 50</time_frame>
    <description>The non-inferiority of HI antibody responses of TIV to that of comparator TIV, in subjects aged 6 to &lt;36 Months, assessed in terms of post vaccination GMTs at three weeks after last vaccination against the three homologous vaccine strains.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparison of Antibody Responses of TIV Versus Comparator TIV in Terms of Percentage of Subjects Achieving Seroconversion or ≥4-fold Increase in HI Titer Against Homologous Strains in Subjects 6 to &lt;36 Months of Age</measure>
    <time_frame>Day 50</time_frame>
    <description>The non-inferiority of HI antibody responses of TIV to that of the licensed comparator TIV assessed in terms of percentage of subjects achieving seroconversion or ≥4-fold increase in HI titers at three weeks after last vaccination against the three homologous vaccine strains.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of Antibody Responses of aTIV With TIV and Comparator TIV in Terms of GMTs Against Homologous Strains (6 to &lt;24 Months)</measure>
    <time_frame>Day 1, Day 50</time_frame>
    <description>The superiority of HI antibody responses, in subjects 6 to &lt;24 months of age, of aTIV compared to TIV and comparator TIV assessed in terms of post vaccination GMTs at three weeks after last vaccination against the three homologous vaccine strains.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of Antibody Responses of aTIV With TIV and Comparator TIV in Terms Percentage of Subjects Achieving Seroconversion or ≥4-fold Increase in HI Titer Against Homologous Strains (6 to &lt;24 Months)</measure>
    <time_frame>Day 50</time_frame>
    <description>The superiority of HI antibody responses, in subjects 6 to &lt;24 months of age, of aTIV compared to TIV and comparator TIV assessed in terms of number of subjects achieving seroconversion at three weeks after last vaccination against the three homologous vaccine strains.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of Antibody Responses of aTIV With TIV and Comparator TIV in Terms of GMTs Against Homologous Strains (6 to &lt;72 Months)-FAS</measure>
    <time_frame>Day 1, Day 50</time_frame>
    <description>The superiority of HI antibody responses, in subjects 6 to &lt;72 months of age, of aTIV compared to TIV and comparator TIV assessed in terms of post vaccination GMTs at three weeks after last vaccination against the three homologous vaccine strains.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of Antibody Responses of aTIV With TIV and Comparator TIV in Terms of Percentage of Subjects Achieving Seroconversion or ≥4 Fold Increase in HI Titers Against Homologous Strains (6 to &lt;72 Months)-FAS</measure>
    <time_frame>Day 50</time_frame>
    <description>The superiority of HI antibody responses, in subjects 6 to &lt;24 months of age, of aTIV compared to TIV and comparator TIV assessed in terms of number of subjects achieving seroconversion ≥4 fold increase in HI titers at three weeks after last vaccination against the three homologous vaccine strains.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The HI GMTs Against Homologous Strains, by Vaccine Group</measure>
    <time_frame>Day 1, Day 29, Day 50, Day 209</time_frame>
    <description>The HI antibody titers against the three homologous strains following vaccination with either aTIV, licensed comparator or TIV, at three weeks and at six months after vaccination are reported as GMTs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Ratio (GMR) of Post- Versus Pre-vaccination HI Titers Against Homologous Strains</measure>
    <time_frame>Day 29, Day 50, Day 209</time_frame>
    <description>The GMR of post-vaccination versus pre-vaccination HI titers against homologous strains, three weeks (day 29/day 1; day 50/day 1)and six months (day 209/day 1) after vaccination with either aTIV, licensed comparator or TIV.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With HI Titers ≥40 Against Homologous Strains, by Vaccine Group</measure>
    <time_frame>Day 1, Day 29, Day 50, Day 209</time_frame>
    <description>The percentage of subjects demonstrating HI titers ≥40,against homologous strains, at three weeks and six months after vaccination with aTIV or licensed comparator or TIV.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects Achieving Seroconversion or ≥4 Fold Increase in HI Titers, Against Homologous Strains</measure>
    <time_frame>Day 29, Day 50, Day 209</time_frame>
    <description>The percentage of subjects achieving seroconversion ≥4 fold increase in HI titers from baseline, against homologous strains, at three weeks and six months after vaccination with ATIV or licensed comparator or TIV.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of Antibody Responses of aTIV With TIV and Comparator TIV in Terms of GMTs Against Homologous Strains, Subjects at Risk/Not at Risk, by Age Subgroup</measure>
    <time_frame>Day 50</time_frame>
    <description>The non-inferiority of Hemagglutination Inhibition (HI) antibody responses of aTIV compared to TIV and comparator TIV assessed in terms of post vaccination GMTs at three weeks after last vaccination against the three homologous vaccine strains, in subjects with a defined set of underlying medical conditions (at risk) and healthy subjects (not at risk), by age sub group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of Antibody Responses of aTIV Versus Comparator TIV and TIV in Terms of Percentage of Subjects Achieving Seroconversion or ≥4-fold Increase in HI Titer Against Homologous Strains in Subjects at Risk/Not at Risk, by Age Subgroup</measure>
    <time_frame>Day 50</time_frame>
    <description>The non-inferiority of HI antibody responses of aTIV to that of the licensed comparator TIV and to investigational TIV was assessed in terms of percentage of subjects achieving seroconversion or ≥4-fold increase in HI titers at three weeks after last vaccination against the three homologous vaccine strains in subjects with a defined set of underlying medical conditions (at risk) and in healthy subjects (not at risk) , by age sub group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of Antibody Responses of TIV Versus Comparator TIV in Terms of Percentage of Subjects Achieving Seroconversion or ≥4-fold Increase in HI Titer Against Homologous Strains in Subjects at Risk/Not at Risk, by Age Sub Group-FAS</measure>
    <time_frame>Day 50</time_frame>
    <description>The superiority of HI antibody responses of aTIV compared to TIV and comparator TIV assessed in terms of of percentage of subjects achieving seroconversion or ≥4-fold increase in HI Titer at three weeks after last vaccination against the three homologous vaccine strains in subjects with a defined set of underlying medical conditions (at risk) and healthy subjects (not at risk), by age sub group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of Antibody Responses of aTIV With TIV and Comparator TIV in Terms of GMTs Against Homologous Strains, at Risk/Not at Risk, by Age Sub Group-FAS</measure>
    <time_frame>Day 50</time_frame>
    <description>The superiority of HI antibody responses of aTIV compared to TIV and comparator TIV assessed in terms of post vaccination GMTs at three weeks after last vaccination against the three homologous vaccine strains, in subjects with a defined set of underlying medical conditions (at risk) and in healthy subjects (not at risk), by age sub group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The HI GMTs Against Heterologous Strains, by Vaccine Group (6 to &lt;72 Months Age Group)</measure>
    <time_frame>Day 1, Day 50, Day 209</time_frame>
    <description>The HI antibody titers against the heterologous strains following vaccination with either aTIV, licensed comparator or TIV, at three weeks and at six months after vaccination are reported as GMTs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects Achieving Seroconversion or ≥4 Fold Increase in HI Titers, Against Heterologous Strains</measure>
    <time_frame>Day 50, Day 209</time_frame>
    <description>The percentage of subjects achieving seroconversion or ≥4 fold increase in HI titers from baseline, against heterologous strains, at three weeks and six months after last vaccination with aTIV or licensed comparator or TIV.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of Antibody Responses of aTIV With TIV and Comparator TIV in Terms of GMTs Against Homologous Strains, After One Vaccination</measure>
    <time_frame>Day 1, Day 29</time_frame>
    <description>To demonstrate the GMTs at three weeks after one dose of aTIV are statistically significantly higher to the corresponding response's of comparator TIV and TIV.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Solicited Adverse Events After Vaccination</measure>
    <time_frame>Day 1 through Day 7 after any vaccination</time_frame>
    <description>The number of subjects reporting any solicited local and systemic adverse events (AEs), following vaccination with aTIV or licensed comparator or TIV.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Unsolicited Adverse Events After Vaccination</measure>
    <time_frame>Day 1 to Day 394</time_frame>
    <description>The number of subjects reporting any unsolicited adverse events (AEs) between Day 1 to Day 50, serious adverse events (SAEs), AE leading to withdrawal (WD), new onset of chronic disease(NOCD), adverse events of special interest following vaccination with aTIV or licensed comparator or TIV throughout the study (Day 1 to Day 394).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">6104</enrollment>
  <condition>Influenza Disease</condition>
  <arm_group>
    <arm_group_label>aTIV (6 to &lt;72 months)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects received an investigational MF59-adjuvanted trivalent influenza vaccine (aTIV), subjects aged between 6 to &lt;36 months received two doses of 0.25 mL each, while subjects aged ≥36 months received two doses of 0.5 mL each, at Days 1 &amp; 29</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparator TIV (6 to &lt;72 months)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects received a licensed comparator trivalent split influenza vaccine (comparator TIV), subjects aged between 6 to &lt;36 months received two doses of 0.25 mL each, while subjects aged ≥36 months received two doses of 0.5 mL each, at Days 1 &amp; 29</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TIV (6 to &lt;72 months)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects received an investigational trivalent split influenza vaccine (TIV), subjects aged between 6 to &lt;36 months received two doses of 0.25 mL each, while subjects aged ≥36 months received two doses of 0.5 mL each, at Days 1 &amp; 29</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Trivalent split influenza vaccine (TIV)</intervention_name>
    <arm_group_label>TIV (6 to &lt;72 months)</arm_group_label>
    <other_name>Agriflu</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MF59-adjuvanted trivalent influenza vaccine (aTIV)</intervention_name>
    <arm_group_label>aTIV (6 to &lt;72 months)</arm_group_label>
    <other_name>Fluad</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Licensed comparator trivalent split influenza vaccine (comparator TIV)</intervention_name>
    <arm_group_label>Comparator TIV (6 to &lt;72 months)</arm_group_label>
    <other_name>Fluzone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1.Children 6 months to 72 months of age.

        Exclusion Criteria:Children

          1. Who had been hospitalized at the time of enrollment

          2. Who had any serious reaction or hypersensitivity to any vaccine component, eggs, or
             chicken protein

          3. Who had known impairment of the immune function

          4. Who had fever interfering with normal daily activities at the time of enrollment

          5. Who had received licensed vaccines within 14 days (for inactivated vaccines) or 28
             days (for live vaccines) prior to enrollment in the study

          6. Concomitant participation in another clinical study

          7. Who had surgery planned during the study period that in the investigator's opinion
             would have interfered with the study visits schedule.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>72 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Vaccines</last_name>
    <role>Study Chair</role>
    <affiliation>Novartis Vaccines</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>401 Paideia Jeronimo Salguero 2835 Piso 1</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>402 Hospital de Ninos Gallo 130</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>403 Instituto Medico Rio Cuarto Hipolito Yrigoyen 1020</name>
      <address>
        <city>Cordoba</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>405 Hospital Pediatrico Nino Jesus Castro Barros 650</name>
      <address>
        <city>Cordoba</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>406 Hospital Nostra Senora de la Misericordia Belgrano 1500</name>
      <address>
        <city>Cordoba</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>407 Centro Pediatrico Caballito Directorio 1658</name>
      <address>
        <city>Cuidad Automa de Beunos Aires</city>
        <zip>1406</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>409 Centro de Salud 16 Alpatacal y Chile</name>
      <address>
        <city>Guaymallen</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>408 Centro de Salud 31 Serpa y Republica del Libano</name>
      <address>
        <city>Mendoza</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>206 Vaccine and Immunology Research Trials Unit University Department of Paediatrics 2nd floor Clarence Reiger Bldg Womens and Childrens Hospital</name>
      <address>
        <city>Adelaide</city>
        <zip>5006</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>201 Royal Children Hospital Department of Respiratory Medicine</name>
      <address>
        <city>Herston</city>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205 Vaccine and Immunisation Research Group Murdoch Childrens Research Institute School Of Population Health</name>
      <address>
        <city>Level 5 207 Bouverie St</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>202 Sydney Children Hospital Department of Immunology and Infectious Diseases</name>
      <address>
        <city>Randwick</city>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>204 National Centre for Immunisation Research and Surveillance Kids Research Institute The Childrens Hospital at Westmead</name>
      <address>
        <city>Westmead</city>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>502 Hospital Clinico Pontificia Universidad Catolica de Chile Marcoleta 357</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>503 Clinica Tabancura Av Tabancura 1185</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>111 DLSHI deCastro De La Salle Health Sciences Institute DBB B Dasmarinas</name>
      <address>
        <city>Cavite</city>
        <zip>4114</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>109 De La Salle Health Sciences Institute</name>
      <address>
        <city>Dbbb Dasmarinas Cavite</city>
        <zip>4114</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>110 De La Salle Health Sciences Institute</name>
      <address>
        <city>Dbbb Dasmarinas Cavite</city>
        <zip>4114</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>103 Philippine General Hospital Taft Avenue</name>
      <address>
        <city>Manila</city>
        <zip>1000</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>107 Philippine General Hospital Taft Avenue</name>
      <address>
        <city>Manila</city>
        <zip>1000</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>112 PGH Lim Philippine General Hospital Taft Avenue</name>
      <address>
        <city>Manila</city>
        <zip>1000</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>114 Philippine General Hospital Taft Avenue</name>
      <address>
        <city>Manila</city>
        <zip>1000</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>105 Mary Chiles General Hospital 667 Gastambide St Sampaloc Manila</name>
      <address>
        <city>Manila</city>
        <zip>1008</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>106 Research Institute for Tropical Medicine Alabang Muntinlupa</name>
      <address>
        <city>Muntinlupa</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>108 RITM Research Institute for Tropical Medicine Department of Health Compound FILINVEST Corporate City Alabang</name>
      <address>
        <city>Muntinlupa</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>101 Philippine Childrens Medical Center Quezon Avenue cor Agham Road Quezon City</name>
      <address>
        <city>Quezon City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>104 Philippine Childrens Medical Center Quezon Avenue cor Agham Road Quezon City</name>
      <address>
        <city>Quezon City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>113 Philippine Childrens Medical Center Quezon Avenue cor Agham Road Quezon City</name>
      <address>
        <city>Quezon City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>102 University of the East Ramon Magsaysay Memorial 64 Aurora Boulevard Barangay Dona Imelda</name>
      <address>
        <city>Quezon</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>305 Worthwhile Clinical Trials Lakeview Hospital 1 Mowbray Avenue</name>
      <address>
        <city>Benoni</city>
        <zip>1500</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>304 Newgate Centre Suite 3</name>
      <address>
        <city>Johannesburg</city>
        <zip>2113</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>303 Emmed Research</name>
      <address>
        <city>Pretoria</city>
        <zip>0084</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>301 Perinatal HIV Research Unit, Baragwanath Hospital</name>
      <address>
        <city>Soweto</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>302 Soweto Clinical Research</name>
      <address>
        <city>Soweto</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Chile</country>
    <country>Philippines</country>
    <country>South Africa</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 30, 2011</study_first_submitted>
  <study_first_submitted_qc>May 2, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 3, 2011</study_first_posted>
  <results_first_submitted>January 27, 2014</results_first_submitted>
  <results_first_submitted_qc>April 3, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 6, 2014</results_first_posted>
  <disposition_first_submitted>November 16, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>November 16, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">November 22, 2012</disposition_first_posted>
  <last_update_submitted>March 4, 2015</last_update_submitted>
  <last_update_submitted_qc>March 4, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Adjuvanted Trivalent Subunit Influenza Vaccine</keyword>
  <keyword>vaccine</keyword>
  <keyword>influenza</keyword>
  <keyword>adjuvant</keyword>
  <keyword>MF-59</keyword>
  <keyword>pediatric</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled from 8 sites in Argentina, 5 sites in Australia, 2 sites in Chile, 12 sites in Philippines, and 5 sites in South Africa.</recruitment_details>
      <pre_assignment_details>4 of the enrolled subjects were not randomized hence were not included in the trial.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>aTIV (6 to &lt;72 Months)</title>
          <description>Subjects received an investigational MF59-adjuvanted trivalent influenza vaccine (aTIV), subjects aged between 6 to &lt;36 months received two doses of 0.25 mL each, while subjects aged ≥36 months received two doses of 0.5 mL each, at Days 1 &amp; 29</description>
        </group>
        <group group_id="P2">
          <title>Comparator TIV (6 to &lt;72 Months)</title>
          <description>Subjects received a licensed comparator trivalent split influenza vaccine (comparator TIV), subjects aged between 6 to &lt;36 months received two doses of 0.25 mL each, while subjects aged ≥36 months received two doses of 0.5 mL each, at Days 1 &amp; 29</description>
        </group>
        <group group_id="P3">
          <title>TIV (6 to &lt;72 Months)</title>
          <description>Subjects received an investigational trivalent split influenza vaccine (TIV), subjects aged between 6 to &lt;36 months received two doses of 0.25 mL each, while subjects aged ≥36 months received two doses of 0.5 mL each, at Days 1 &amp; 29</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3136"/>
                <participants group_id="P2" count="1478"/>
                <participants group_id="P3" count="1486"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2983"/>
                <participants group_id="P2" count="1389"/>
                <participants group_id="P3" count="1408"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="153"/>
                <participants group_id="P2" count="89"/>
                <participants group_id="P3" count="78"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="62"/>
                <participants group_id="P2" count="29"/>
                <participants group_id="P3" count="29"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="77"/>
                <participants group_id="P2" count="51"/>
                <participants group_id="P3" count="38"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Inappropriate enrollment</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative reason</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unable to Classify</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>aTIV (6 to &lt;72 Months)</title>
          <description>Subjects received an investigational MF59-adjuvanted trivalent influenza vaccine (aTIV), subjects aged between 6 to &lt;36 months received two doses of 0.25 mL each, while subjects aged ≥36 months received two doses of 0.5 mL each, at Days 1 &amp; 29</description>
        </group>
        <group group_id="B2">
          <title>Comparator TIV (6 to &lt;72 Months)</title>
          <description>Subjects received a licensed comparator trivalent split influenza vaccine (comparator TIV), subjects aged between 6 to &lt;36 months received two doses of 0.25 mL each, while subjects aged ≥36 months received two doses of 0.5 mL each, at Days 1 &amp; 29</description>
        </group>
        <group group_id="B3">
          <title>TIV (6 to &lt;72 Months)</title>
          <description>Subjects received an investigational trivalent split influenza vaccine (TIV), subjects aged between 6 to &lt;36 months received two doses of 0.25 mL each, while subjects aged ≥36 months received two doses of 0.5 mL each, at Days 1 &amp; 29</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3136"/>
            <count group_id="B2" value="1478"/>
            <count group_id="B3" value="1486"/>
            <count group_id="B4" value="6100"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.1" spread="18.6"/>
                    <measurement group_id="B2" value="30.0" spread="16.9"/>
                    <measurement group_id="B3" value="30.2" spread="16.9"/>
                    <measurement group_id="B4" value="33.7" spread="18.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1545"/>
                    <measurement group_id="B2" value="745"/>
                    <measurement group_id="B3" value="731"/>
                    <measurement group_id="B4" value="3021"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1591"/>
                    <measurement group_id="B2" value="733"/>
                    <measurement group_id="B3" value="755"/>
                    <measurement group_id="B4" value="3079"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Comparison of Antibody Responses of aTIV With TIV and Comparator TIV in Terms of Geometric Mean Titers (GMTs) Against Homologous Strains</title>
        <description>The non-inferiority of Hemagglutination Inhibition (HI) antibody responses of aTIV compared to TIV and comparator TIV assessed in terms of post vaccination GMTs at three weeks after last vaccination against the three homologous vaccine strains.</description>
        <time_frame>Day 1, Day 50</time_frame>
        <population>Analysis was done on the Per Protocol Set (PPS) i.e all subjects in the enrolled population who correctly received the study vaccine, provided evaluable serum samples at relevant time-points and had no major protocol violations as defined prior to unblinding.</population>
        <group_list>
          <group group_id="O1">
            <title>aTIV (6 to &lt;72 Months)</title>
            <description>Subjects received an investigational MF59-adjuvanted trivalent influenza vaccine (aTIV), subjects aged between 6 to &lt;36 months received two doses (Day 1 &amp; 29) while subjects aged ≥36 months received one dose (at Day 1) of the vaccine</description>
          </group>
          <group group_id="O2">
            <title>Comparator TIV (6 to &lt;72 Months)</title>
            <description>Subjects received a licensed comparator trivalent split influenza vaccine (comparator TIV), subjects aged between 6 to &lt;36 months received two doses (Day 1 &amp; 29) while subjects aged ≥36 months received one dose (at Day 1) of the vaccine</description>
          </group>
          <group group_id="O3">
            <title>TIV (6 to &lt;72 Months)</title>
            <description>Subjects received an investigational trivalent split influenza vaccine (TIV), subjects aged between 6 to &lt;36 months received two doses (Day 1 &amp; 29) while subjects aged ≥36 months received one dose (Day 1) of the vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of Antibody Responses of aTIV With TIV and Comparator TIV in Terms of Geometric Mean Titers (GMTs) Against Homologous Strains</title>
          <description>The non-inferiority of Hemagglutination Inhibition (HI) antibody responses of aTIV compared to TIV and comparator TIV assessed in terms of post vaccination GMTs at three weeks after last vaccination against the three homologous vaccine strains.</description>
          <population>Analysis was done on the Per Protocol Set (PPS) i.e all subjects in the enrolled population who correctly received the study vaccine, provided evaluable serum samples at relevant time-points and had no major protocol violations as defined prior to unblinding.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="682"/>
                <count group_id="O2" value="757"/>
                <count group_id="O3" value="765"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1 - Day 1 (N=681,757,765)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28" lower_limit="24" upper_limit="33"/>
                    <measurement group_id="O2" value="24" lower_limit="21" upper_limit="28"/>
                    <measurement group_id="O3" value="27" lower_limit="23" upper_limit="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H1N1 - Day 50 (N=681,757,765)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1537" lower_limit="1382" upper_limit="1709"/>
                    <measurement group_id="O2" value="629" lower_limit="567" upper_limit="698"/>
                    <measurement group_id="O3" value="480" lower_limit="433" upper_limit="532"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2 - Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40" lower_limit="35" upper_limit="47"/>
                    <measurement group_id="O2" value="42" lower_limit="36" upper_limit="49"/>
                    <measurement group_id="O3" value="44" lower_limit="38" upper_limit="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2 - Day 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1908" lower_limit="1785" upper_limit="2040"/>
                    <measurement group_id="O2" value="1012" lower_limit="948" upper_limit="1080"/>
                    <measurement group_id="O3" value="803" lower_limit="752" upper_limit="857"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B strain Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.87" lower_limit="9.08" upper_limit="11"/>
                    <measurement group_id="O2" value="10" lower_limit="9.41" upper_limit="11"/>
                    <measurement group_id="O3" value="10" lower_limit="9.33" upper_limit="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B strain Day 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="492" lower_limit="450" upper_limit="537"/>
                    <measurement group_id="O2" value="160" lower_limit="147" upper_limit="175"/>
                    <measurement group_id="O3" value="157" lower_limit="144" upper_limit="171"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Noninferiority was established if the lower limit of the confidence interval of the day 50 ratio of GMTs was &gt;0.667</non_inferiority_desc>
            <param_type>GMT ratio (H1N1 strain)</param_type>
            <param_value>2.44</param_value>
            <ci_percent>97.6</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.06</ci_lower_limit>
            <ci_upper_limit>2.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Noninferiority was established if the lower limit of the confidence interval of the day 50 ratio of GMTs was &gt;0.667</non_inferiority_desc>
            <param_type>GMT ratio (H3N2 strain)</param_type>
            <param_value>1.89</param_value>
            <ci_percent>97.6</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.69</ci_lower_limit>
            <ci_upper_limit>2.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Noninferiority was established if the lower limit of the confidence interval of the day 50 ratio of GMTs was &gt;0.667</non_inferiority_desc>
            <param_type>GMT ratio (B strain)</param_type>
            <param_value>3.07</param_value>
            <ci_percent>97.6</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.66</ci_lower_limit>
            <ci_upper_limit>3.54</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Noninferiority was established if the lower limit of the confidence interval of the day 50 ratio of GMTs was &gt;0.667</non_inferiority_desc>
            <param_type>GMT ratio (H1N1 strain)</param_type>
            <param_value>3.2</param_value>
            <ci_percent>97.6</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.7</ci_lower_limit>
            <ci_upper_limit>3.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Noninferiority was established if the lower limit of the confidence interval of the day 50 ratio of GMTs was &gt;0.667</non_inferiority_desc>
            <param_type>GMT ratio (H3N2 strain)</param_type>
            <param_value>2.38</param_value>
            <ci_percent>97.6</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.14</ci_lower_limit>
            <ci_upper_limit>2.65</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Noninferiority was established if the lower limit of the confidence interval of the day 50 ratio of GMTs was &gt;0.667</non_inferiority_desc>
            <param_type>GMT ratio (B strain)</param_type>
            <param_value>3.14</param_value>
            <ci_percent>97.6</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.72</ci_lower_limit>
            <ci_upper_limit>3.62</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Comparison of Antibody Responses of aTIV With TIV and Comparator TIV in Terms of Percentage of Subjects Achieving Seroconversion or ≥4-fold Increase in HI Titers Against Homologous Strains</title>
        <description>The non-inferiority of HI antibody responses of aTIV compared to TIV and comparator TIV assessed in terms of percentage of subjects achieving seroconversion or ≥4-fold increase in HI titers at three weeks after last vaccination against the three homologous vaccine strains.
Seroconversion defined as prevaccination HI titer &lt;10 and postvaccination HI titer ≥40 or at least a 4-fold increase in HI titers from prevaccination HI titer ≥10.</description>
        <time_frame>Day 50</time_frame>
        <population>Analysis was done on the PPS.</population>
        <group_list>
          <group group_id="O1">
            <title>aTIV (6 to &lt;72 Months)</title>
            <description>Subjects received an investigational MF59-adjuvanted trivalent influenza vaccine (aTIV), subjects aged between 6 to &lt;36 months received two doses of 0.25 mL each, while subjects aged ≥36 months received two doses of 0.5 mL each, at Days 1 &amp; 29</description>
          </group>
          <group group_id="O2">
            <title>Comparator TIV (6 to &lt;72 Months)</title>
            <description>Subjects received a licensed comparator trivalent split influenza vaccine (comparator TIV), subjects aged between 6 to &lt;36 months received two doses of 0.25 mL each, while subjects aged ≥36 months received two doses of 0.5 mL each, at Days 1 &amp; 29</description>
          </group>
          <group group_id="O3">
            <title>TIV (6 to &lt;72 Months)</title>
            <description>Subjects received an investigational trivalent split influenza vaccine (TIV), subjects aged between 6 to &lt;36 months received two doses of 0.25 mL each, while subjects aged ≥36 months received two doses of 0.5 mL each, at Days 1 &amp; 29</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of Antibody Responses of aTIV With TIV and Comparator TIV in Terms of Percentage of Subjects Achieving Seroconversion or ≥4-fold Increase in HI Titers Against Homologous Strains</title>
          <description>The non-inferiority of HI antibody responses of aTIV compared to TIV and comparator TIV assessed in terms of percentage of subjects achieving seroconversion or ≥4-fold increase in HI titers at three weeks after last vaccination against the three homologous vaccine strains.
Seroconversion defined as prevaccination HI titer &lt;10 and postvaccination HI titer ≥40 or at least a 4-fold increase in HI titers from prevaccination HI titer ≥10.</description>
          <population>Analysis was done on the PPS.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="682"/>
                <count group_id="O2" value="757"/>
                <count group_id="O3" value="765"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1 - (N=680,757,765)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.9" lower_limit="90.8" upper_limit="94.8"/>
                    <measurement group_id="O2" value="84.5" lower_limit="81.8" upper_limit="87.1"/>
                    <measurement group_id="O3" value="79.4" lower_limit="76.3" upper_limit="82.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.5" lower_limit="94.8" upper_limit="97.7"/>
                    <measurement group_id="O2" value="92.3" lower_limit="90.2" upper_limit="94.1"/>
                    <measurement group_id="O3" value="89.4" lower_limit="87" upper_limit="91.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98" lower_limit="96.6" upper_limit="98.9"/>
                    <measurement group_id="O2" value="86" lower_limit="83.3" upper_limit="88.4"/>
                    <measurement group_id="O3" value="84.6" lower_limit="81.8" upper_limit="87.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the lower bound of the confidence interval for day 50 vaccine group difference was &gt;-10%.</non_inferiority_desc>
            <param_type>Group difference (H1N1 strain)</param_type>
            <param_value>9.09</param_value>
            <ci_percent>97.6</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.48</ci_lower_limit>
            <ci_upper_limit>12.69</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the lower bound of the confidence interval for day 50 vaccine group difference was &gt;-10%</non_inferiority_desc>
            <param_type>Group difference (H3N2 strain)</param_type>
            <param_value>4.07</param_value>
            <ci_percent>97.6</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.58</ci_lower_limit>
            <ci_upper_limit>6.55</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the lower bound of the confidence interval for day 50 vaccine group difference was &gt; -10%</non_inferiority_desc>
            <param_type>Group difference (B strain)</param_type>
            <param_value>11.82</param_value>
            <ci_percent>97.6</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>8.72</ci_lower_limit>
            <ci_upper_limit>14.92</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the lower bound of the confidence interval for day 50 vaccine group difference was &gt; -10%</non_inferiority_desc>
            <param_type>Group difference (H1N1 strain)</param_type>
            <param_value>14.21</param_value>
            <ci_percent>97.6</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>10.3</ci_lower_limit>
            <ci_upper_limit>18.13</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the lower bound of the confidence interval for day 50 vaccine group difference was &gt; -10%</non_inferiority_desc>
            <param_type>Group difference (H3N2 strain)</param_type>
            <param_value>7.31</param_value>
            <ci_percent>97.6</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.47</ci_lower_limit>
            <ci_upper_limit>10.14</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the lower bound of the confidence interval for day 50 vaccine group difference was &gt; -10%</non_inferiority_desc>
            <param_type>Group difference (B strain)</param_type>
            <param_value>11.1</param_value>
            <ci_percent>97.6</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>8.11</ci_lower_limit>
            <ci_upper_limit>14.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Comparison of Antibody Responses of TIV Versus Comparator TIV in Terms of Geometric Mean Titers (GMTs) Against Homologous Strains (6 to &lt;36 Months)</title>
        <description>The non-inferiority of HI antibody responses of TIV to that of comparator TIV, in subjects aged 6 to &lt;36 Months, assessed in terms of post vaccination GMTs at three weeks after last vaccination against the three homologous vaccine strains.</description>
        <time_frame>Day 1, Day 50</time_frame>
        <population>Analysis was done on the PPS.</population>
        <group_list>
          <group group_id="O1">
            <title>TIV (6 to &lt;36months)</title>
            <description>Subjects received two doses of 0.25 mL each, of investigational trivalent split influenza vaccine (TIV), at Days 1 &amp; 29</description>
          </group>
          <group group_id="O2">
            <title>Comparator TIV (6 to &lt;36months)</title>
            <description>Subjects received two doses of 0.25 mL each, of the licensed trivalent split influenza vaccine (comparator TIV), at Days 1 &amp; 29</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of Antibody Responses of TIV Versus Comparator TIV in Terms of Geometric Mean Titers (GMTs) Against Homologous Strains (6 to &lt;36 Months)</title>
          <description>The non-inferiority of HI antibody responses of TIV to that of comparator TIV, in subjects aged 6 to &lt;36 Months, assessed in terms of post vaccination GMTs at three weeks after last vaccination against the three homologous vaccine strains.</description>
          <population>Analysis was done on the PPS.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="642"/>
                <count group_id="O2" value="635"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1 - Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23" lower_limit="20" upper_limit="27"/>
                    <measurement group_id="O2" value="20" lower_limit="17" upper_limit="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H1N1 - Day 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="370" lower_limit="328" upper_limit="419"/>
                    <measurement group_id="O2" value="487" lower_limit="431" upper_limit="551"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2 - Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29" lower_limit="24" upper_limit="33"/>
                    <measurement group_id="O2" value="28" lower_limit="24" upper_limit="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2 - Day 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="698" lower_limit="650" upper_limit="749"/>
                    <measurement group_id="O2" value="912" lower_limit="849" upper_limit="980"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B strain Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.42" lower_limit="8.63" upper_limit="10"/>
                    <measurement group_id="O2" value="9.42" lower_limit="8.62" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B -strain Day 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="144" lower_limit="130" upper_limit="159"/>
                    <measurement group_id="O2" value="152" lower_limit="138" upper_limit="168"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the lower bound of the confidence interval for day 50 GMT group ratios was &gt;0.667</non_inferiority_desc>
            <param_type>Group ratio (H1N1 strain)</param_type>
            <param_value>0.76</param_value>
            <ci_percent>97.4</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.62</ci_lower_limit>
            <ci_upper_limit>0.93</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the lower bound of the confidence interval for day 50 GMT group ratios was &gt;0.667</non_inferiority_desc>
            <param_type>GMT ratio (H3N2 strain)</param_type>
            <param_value>0.77</param_value>
            <ci_percent>97.4</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.68</ci_lower_limit>
            <ci_upper_limit>0.86</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the lower bound of the confidence interval for day 50 GMT group ratios was &gt;0.667</non_inferiority_desc>
            <param_type>GMT ratio (B strain)</param_type>
            <param_value>0.94</param_value>
            <ci_percent>97.4</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.8</ci_lower_limit>
            <ci_upper_limit>1.11</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Comparison of Antibody Responses of TIV Versus Comparator TIV in Terms of Percentage of Subjects Achieving Seroconversion or ≥4-fold Increase in HI Titer Against Homologous Strains in Subjects 6 to &lt;36 Months of Age</title>
        <description>The non-inferiority of HI antibody responses of TIV to that of the licensed comparator TIV assessed in terms of percentage of subjects achieving seroconversion or ≥4-fold increase in HI titers at three weeks after last vaccination against the three homologous vaccine strains.</description>
        <time_frame>Day 50</time_frame>
        <population>Subjects aged 6 through &lt;36 months of age - Per Protocol Set (PPS).</population>
        <group_list>
          <group group_id="O1">
            <title>TIV (6 to &lt;36months)</title>
            <description>Subjects received two doses of 0.25 mL each, of investigational trivalent split influenza vaccine (TIV), at Days 1 &amp; 29</description>
          </group>
          <group group_id="O2">
            <title>Comparator TIV (6 to &lt;36months)</title>
            <description>Subjects received two doses of 0.25 mL each, of the licensed trivalent split influenza vaccine (comparator TIV), at Days 1 &amp; 29</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of Antibody Responses of TIV Versus Comparator TIV in Terms of Percentage of Subjects Achieving Seroconversion or ≥4-fold Increase in HI Titer Against Homologous Strains in Subjects 6 to &lt;36 Months of Age</title>
          <description>The non-inferiority of HI antibody responses of TIV to that of the licensed comparator TIV assessed in terms of percentage of subjects achieving seroconversion or ≥4-fold increase in HI titers at three weeks after last vaccination against the three homologous vaccine strains.</description>
          <population>Subjects aged 6 through &lt;36 months of age - Per Protocol Set (PPS).</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="642"/>
                <count group_id="O2" value="635"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.8" lower_limit="75.5" upper_limit="81.9"/>
                    <measurement group_id="O2" value="84.1" lower_limit="81" upper_limit="86.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.9" lower_limit="87.3" upper_limit="92.1"/>
                    <measurement group_id="O2" value="92.6" lower_limit="90.3" upper_limit="94.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.7" lower_limit="79.6" upper_limit="85.6"/>
                    <measurement group_id="O2" value="85.5" lower_limit="82.5" upper_limit="88.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the lower bound of the confidence interval for day 50 vaccine group differences was &gt; -10%</non_inferiority_desc>
            <param_type>Group difference (H1N1 strain)</param_type>
            <param_value>-5.3</param_value>
            <ci_percent>97.4</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.13</ci_lower_limit>
            <ci_upper_limit>-0.47</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the lower bound of the confidence interval for day 50 vaccine group differences was &gt; -10%</non_inferiority_desc>
            <param_type>Group difference (H3N2 strain)</param_type>
            <param_value>-2.84</param_value>
            <ci_percent>97.4</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.16</ci_lower_limit>
            <ci_upper_limit>0.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the lower bound of the confidence interval for day 50 vaccine group differences was &gt; -10%</non_inferiority_desc>
            <param_type>Group difference (B strain)</param_type>
            <param_value>-2.49</param_value>
            <ci_percent>97.4</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.01</ci_lower_limit>
            <ci_upper_limit>2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparison of Antibody Responses of aTIV With TIV and Comparator TIV in Terms of GMTs Against Homologous Strains (6 to &lt;24 Months)</title>
        <description>The superiority of HI antibody responses, in subjects 6 to &lt;24 months of age, of aTIV compared to TIV and comparator TIV assessed in terms of post vaccination GMTs at three weeks after last vaccination against the three homologous vaccine strains.</description>
        <time_frame>Day 1, Day 50</time_frame>
        <population>Analysis was done on the Full Analysis Set (FAS) i.e all enrolled subjects who received study vaccination and provided serum samples.</population>
        <group_list>
          <group group_id="O1">
            <title>aTIV (6 to &lt;24 Months)</title>
            <description>Subjects received two doses of 0.25 mL each, of the investigational MF59-adjuvanted trivalent split influenza vaccine (aTIV), at Days 1 &amp; 29</description>
          </group>
          <group group_id="O2">
            <title>Comparator TIV (6 to &lt;24 Months)</title>
            <description>Subjects received two doses of 0.25 mL each, of the licensed comparator trivalent split influenza vaccine (comparator TIV), at Days 1 &amp; 29</description>
          </group>
          <group group_id="O3">
            <title>TIV (6 to &lt;24 Months)</title>
            <description>Subjects received two doses of 0.25 mL each, of the investigational trivalent split influenza vaccine (TIV), at Days 1 &amp; 29</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of Antibody Responses of aTIV With TIV and Comparator TIV in Terms of GMTs Against Homologous Strains (6 to &lt;24 Months)</title>
          <description>The superiority of HI antibody responses, in subjects 6 to &lt;24 months of age, of aTIV compared to TIV and comparator TIV assessed in terms of post vaccination GMTs at three weeks after last vaccination against the three homologous vaccine strains.</description>
          <population>Analysis was done on the Full Analysis Set (FAS) i.e all enrolled subjects who received study vaccination and provided serum samples.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="266"/>
                <count group_id="O2" value="389"/>
                <count group_id="O3" value="387"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1 - Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12" lower_limit="9.52" upper_limit="14"/>
                    <measurement group_id="O2" value="9.87" lower_limit="8.36" upper_limit="12"/>
                    <measurement group_id="O3" value="12" lower_limit="9.95" upper_limit="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H1N1 - Day 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1080" lower_limit="899" upper_limit="1297"/>
                    <measurement group_id="O2" value="298" lower_limit="256" upper_limit="347"/>
                    <measurement group_id="O3" value="205" lower_limit="176" upper_limit="238"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2 - Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15" lower_limit="12" upper_limit="19"/>
                    <measurement group_id="O2" value="15" lower_limit="12" upper_limit="18"/>
                    <measurement group_id="O3" value="17" lower_limit="14" upper_limit="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2 - Day 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1709" lower_limit="1536" upper_limit="1903"/>
                    <measurement group_id="O2" value="758" lower_limit="694" upper_limit="828"/>
                    <measurement group_id="O3" value="552" lower_limit="505" upper_limit="603"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B strain Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.75" lower_limit="6.83" upper_limit="8.78"/>
                    <measurement group_id="O2" value="8.18" lower_limit="7.37" upper_limit="9.07"/>
                    <measurement group_id="O3" value="7.92" lower_limit="7.14" upper_limit="8.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B strain Day 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="616" lower_limit="534" upper_limit="711"/>
                    <measurement group_id="O2" value="133" lower_limit="118" upper_limit="149"/>
                    <measurement group_id="O3" value="112" lower_limit="100" upper_limit="127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Superiority was concluded if the lower limit of the confidence interval for the day 50 vaccine group GMT ratios for at least 2 homologous strains was &gt;1.5.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMT ratio (H1N1 strain)</param_type>
            <param_value>3.63</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.86</ci_lower_limit>
            <ci_upper_limit>4.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>superiority was concluded if the lower limit of the confidence interval of the day 50 vaccine group GMT ratios for at least 2 homologous strains was &gt;1.5</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMT ratio (H3N2 strain)</param_type>
            <param_value>2.25</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.96</ci_lower_limit>
            <ci_upper_limit>2.59</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>superiority was concluded if the lower limit of the confidence interval of the day 50 vaccine group GMT ratios for at least 2 homologous strains was &gt;1.5</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMT ratio (B strain)</param_type>
            <param_value>4.64</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.86</ci_lower_limit>
            <ci_upper_limit>5.59</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>superiority was concluded if the lower limit of the confidence interval of the day 50 vaccine group GMT ratios for at least 2 homologous strains was &gt;1.5</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMT ratio (H1N1 strain)</param_type>
            <param_value>5.28</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.16</ci_lower_limit>
            <ci_upper_limit>6.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>superiority was concluded if the lower limit of the confidence interval of the day 50 vaccine group GMT ratios for at least 2 homologous strains was &gt;1.5</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMT ratio (H3N2 strain)</param_type>
            <param_value>3.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.69</ci_lower_limit>
            <ci_upper_limit>3.56</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>superiority was concluded if the lower limit of the confidence interval of the day 50 vaccine group GMT ratios for at least 2 homologous strains was &gt;1.5</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMT ratio (B strain)</param_type>
            <param_value>4.64</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.86</ci_lower_limit>
            <ci_upper_limit>5.59</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparison of Antibody Responses of aTIV With TIV and Comparator TIV in Terms Percentage of Subjects Achieving Seroconversion or ≥4-fold Increase in HI Titer Against Homologous Strains (6 to &lt;24 Months)</title>
        <description>The superiority of HI antibody responses, in subjects 6 to &lt;24 months of age, of aTIV compared to TIV and comparator TIV assessed in terms of number of subjects achieving seroconversion at three weeks after last vaccination against the three homologous vaccine strains.</description>
        <time_frame>Day 50</time_frame>
        <population>Analysis was done on the FAS</population>
        <group_list>
          <group group_id="O1">
            <title>aTIV (6 to &lt;24 Months)</title>
            <description>Subjects received two doses of 0.25 mL each, of the investigational MF59-adjuvanted trivalent split influenza vaccine (aTIV), at Days 1 &amp; 29</description>
          </group>
          <group group_id="O2">
            <title>Comparator TIV (6 to &lt;24 Months)</title>
            <description>Subjects received two doses of 0.25 mL each, of the licensed comparator trivalent split influenza vaccine (comparator TIV), at Days 1 &amp; 29</description>
          </group>
          <group group_id="O3">
            <title>TIV (6 to &lt;24 Months)</title>
            <description>Subjects received two doses of 0.25 mL each, of the investigational trivalent split influenza vaccine (TIV), at Days 1 &amp; 29</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of Antibody Responses of aTIV With TIV and Comparator TIV in Terms Percentage of Subjects Achieving Seroconversion or ≥4-fold Increase in HI Titer Against Homologous Strains (6 to &lt;24 Months)</title>
          <description>The superiority of HI antibody responses, in subjects 6 to &lt;24 months of age, of aTIV compared to TIV and comparator TIV assessed in terms of number of subjects achieving seroconversion at three weeks after last vaccination against the three homologous vaccine strains.</description>
          <population>Analysis was done on the FAS</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="266"/>
                <count group_id="O2" value="389"/>
                <count group_id="O3" value="387"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.5" lower_limit="92.3" upper_limit="97.7"/>
                    <measurement group_id="O2" value="85.1" lower_limit="81.2" upper_limit="88.5"/>
                    <measurement group_id="O3" value="77.8" lower_limit="73.3" upper_limit="81.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.1" lower_limit="95.7" upper_limit="99.4"/>
                    <measurement group_id="O2" value="95.6" lower_limit="93.1" upper_limit="97.4"/>
                    <measurement group_id="O3" value="92.5" lower_limit="89.4" upper_limit="94.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.1" lower_limit="95.7" upper_limit="99.4"/>
                    <measurement group_id="O2" value="85.4" lower_limit="81.4" upper_limit="88.7"/>
                    <measurement group_id="O3" value="79.3" lower_limit="75" upper_limit="83.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>superiority was concluded if the lower limit of the confidence interval of day 50 vaccine group difference,for at least 2 homologous strains, was &gt;10%</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Group difference (H1N1 strain)</param_type>
            <param_value>10.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>6.1</ci_lower_limit>
            <ci_upper_limit>14.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>superiority was concluded if the lower limit of the confidence interval of day 50 vaccine group difference,for at least 2 homologous strains, was &gt;10%</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Group difference (H3N2 strain)</param_type>
            <param_value>2.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.12</ci_lower_limit>
            <ci_upper_limit>5.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>superiority was concluded if the lower limit of the confidence interval of day 50 vaccine group difference,for at least 2 homologous strains, was &gt;10%</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Group difference (B strain)</param_type>
            <param_value>12.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>8.9</ci_lower_limit>
            <ci_upper_limit>16.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>superiority was concluded if the lower limit of the confidence interval of day 50 vaccine group difference,for at least 2 homologous strains, was &gt;10%</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Group difference (H1N1 strain)</param_type>
            <param_value>17.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>12.9</ci_lower_limit>
            <ci_upper_limit>22.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>superiority was concluded if the lower limit of the confidence interval of day 50 vaccine group difference,for at least 2 homologous strains, was &gt;10%</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Group difference (H3N2 strain)</param_type>
            <param_value>5.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.5</ci_lower_limit>
            <ci_upper_limit>8.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>superiority was concluded if the lower limit of the confidence interval of day 50 vaccine group difference,for at least 2 homologous strains, was &gt;10%</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Group difference (B strain)</param_type>
            <param_value>18.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>14.4</ci_lower_limit>
            <ci_upper_limit>23.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparison of Antibody Responses of aTIV With TIV and Comparator TIV in Terms of GMTs Against Homologous Strains (6 to &lt;72 Months)-FAS</title>
        <description>The superiority of HI antibody responses, in subjects 6 to &lt;72 months of age, of aTIV compared to TIV and comparator TIV assessed in terms of post vaccination GMTs at three weeks after last vaccination against the three homologous vaccine strains.</description>
        <time_frame>Day 1, Day 50</time_frame>
        <population>Analysis was done on the FAS</population>
        <group_list>
          <group group_id="O1">
            <title>aTIV (6 to &lt;72 Months)</title>
            <description>Subjects received an investigational MF59-adjuvanted trivalent influenza vaccine (aTIV), subjects aged between 6 to &lt;36 months received two doses of 0.25 mL each, while subjects aged ≥36 months received two doses of 0.5 mL each, at Days 1 &amp; 29</description>
          </group>
          <group group_id="O2">
            <title>Comparator TIV (6 to &lt;72 Months)</title>
            <description>Subjects received a licensed comparator trivalent split influenza vaccine (comparator TIV), subjects aged between 6 to &lt;36 months received two doses of 0.25 mL each, while subjects aged ≥36 months received two doses of 0.5 mL each, at Days 1 &amp; 29</description>
          </group>
          <group group_id="O3">
            <title>TIV (6 to &lt;72 Months)</title>
            <description>Subjects received an investigational trivalent split influenza vaccine (TIV), subjects aged between 6 to &lt;36 months received two doses of 0.25 mL each, while subjects aged ≥36 months received two doses of 0.5 mL each, at Days 1 &amp; 29</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of Antibody Responses of aTIV With TIV and Comparator TIV in Terms of GMTs Against Homologous Strains (6 to &lt;72 Months)-FAS</title>
          <description>The superiority of HI antibody responses, in subjects 6 to &lt;72 months of age, of aTIV compared to TIV and comparator TIV assessed in terms of post vaccination GMTs at three weeks after last vaccination against the three homologous vaccine strains.</description>
          <population>Analysis was done on the FAS</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="747"/>
                <count group_id="O2" value="839"/>
                <count group_id="O3" value="849"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1 - Day 1 (N=746,839,849)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29" lower_limit="25" upper_limit="33"/>
                    <measurement group_id="O2" value="24" lower_limit="21" upper_limit="28"/>
                    <measurement group_id="O3" value="27" lower_limit="23" upper_limit="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H1N1 - Day 50 (N=746,839,849)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1519" lower_limit="1372" upper_limit="1683"/>
                    <measurement group_id="O2" value="637" lower_limit="577" upper_limit="704"/>
                    <measurement group_id="O3" value="473" lower_limit="428" upper_limit="522"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2 - Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41" lower_limit="36" upper_limit="48"/>
                    <measurement group_id="O2" value="42" lower_limit="37" upper_limit="49"/>
                    <measurement group_id="O3" value="44" lower_limit="38" upper_limit="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2 - Day 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1909" lower_limit="1791" upper_limit="2035"/>
                    <measurement group_id="O2" value="1016" lower_limit="954" upper_limit="1081"/>
                    <measurement group_id="O3" value="796" lower_limit="748" upper_limit="847"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B strain - Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.97" lower_limit="9.2" upper_limit="11"/>
                    <measurement group_id="O2" value="10" lower_limit="9.49" upper_limit="11"/>
                    <measurement group_id="O3" value="10" lower_limit="9.33" upper_limit="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B strain-Day 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="480" lower_limit="441" upper_limit="523"/>
                    <measurement group_id="O2" value="164" lower_limit="151" upper_limit="178"/>
                    <measurement group_id="O3" value="156" lower_limit="144" upper_limit="169"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>superiority was concluded if the lower limit of the confidence interval of the day 50 vaccine group GMT ratios for at least 2 homologous strains was &gt;1.5</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMT Ratio (H1N1 strain)</param_type>
            <param_value>2.38</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.07</ci_lower_limit>
            <ci_upper_limit>2.75</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>superiority was concluded if the lower limit of the confidence interval of the day 50 vaccine group GMT ratios for at least 2 homologous strains was &gt;1.5</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMT Ratio (H3N2 strain)</param_type>
            <param_value>1.88</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.72</ci_lower_limit>
            <ci_upper_limit>2.06</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>superiority was concluded if the lower limit of the confidence interval of the day 50 vaccine group GMT ratios for at least 2 homologous strains was &gt;1.5</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMT Ratio (B strain)</param_type>
            <param_value>2.93</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.6</ci_lower_limit>
            <ci_upper_limit>3.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>superiority was concluded if the lower limit of the confidence interval of the day 50 vaccine group GMT ratios for at least 2 homologous strains was &gt;1.5</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMT Ratio (H1N1 strain)</param_type>
            <param_value>3.21</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.79</ci_lower_limit>
            <ci_upper_limit>3.71</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>superiority was concluded if the lower limit of the confidence interval of the day 50 vaccine group GMT ratios for at least 2 homologous strains was &gt;1.5</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMT Ratio (H3N2 strain)</param_type>
            <param_value>2.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.19</ci_lower_limit>
            <ci_upper_limit>2.62</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>superiority was concluded if the lower limit of the confidence interval of the day 50 vaccine group GMT ratios for at least 2 homologous strains was &gt;1.5</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMT Ratio (B strain)</param_type>
            <param_value>3.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.73</ci_lower_limit>
            <ci_upper_limit>3.47</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparison of Antibody Responses of aTIV With TIV and Comparator TIV in Terms of Percentage of Subjects Achieving Seroconversion or ≥4 Fold Increase in HI Titers Against Homologous Strains (6 to &lt;72 Months)-FAS</title>
        <description>The superiority of HI antibody responses, in subjects 6 to &lt;24 months of age, of aTIV compared to TIV and comparator TIV assessed in terms of number of subjects achieving seroconversion ≥4 fold increase in HI titers at three weeks after last vaccination against the three homologous vaccine strains.</description>
        <time_frame>Day 50</time_frame>
        <population>Analysis was done on the FAS</population>
        <group_list>
          <group group_id="O1">
            <title>aTIV (6 to &lt;72 Months)</title>
            <description>Subjects received an investigational MF59-adjuvanted trivalent influenza vaccine (aTIV), subjects aged between 6 to &lt;36 months received two doses of 0.25 mL each, while subjects aged ≥36 months received two doses of 0.5 mL each, at Days 1 &amp; 29</description>
          </group>
          <group group_id="O2">
            <title>Comparator TIV (6 to &lt;72 Months)</title>
            <description>Subjects received a licensed comparator trivalent split influenza vaccine (comparator TIV), subjects aged between 6 to &lt;36 months received two doses of 0.25 mL each, while subjects aged ≥36 months received two doses of 0.5 mL each, at Days 1 &amp; 29</description>
          </group>
          <group group_id="O3">
            <title>TIV (6 to &lt;72 Months)</title>
            <description>Subjects received an investigational trivalent split influenza vaccine (TIV), subjects aged between 6 to &lt;36 months received two doses of 0.25 mL each, while subjects aged ≥36 months received two doses of 0.5 mL each, at Days 1 &amp; 29</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of Antibody Responses of aTIV With TIV and Comparator TIV in Terms of Percentage of Subjects Achieving Seroconversion or ≥4 Fold Increase in HI Titers Against Homologous Strains (6 to &lt;72 Months)-FAS</title>
          <description>The superiority of HI antibody responses, in subjects 6 to &lt;24 months of age, of aTIV compared to TIV and comparator TIV assessed in terms of number of subjects achieving seroconversion ≥4 fold increase in HI titers at three weeks after last vaccination against the three homologous vaccine strains.</description>
          <population>Analysis was done on the FAS</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="747"/>
                <count group_id="O2" value="839"/>
                <count group_id="O3" value="849"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.8" lower_limit="90.7" upper_limit="94.5"/>
                    <measurement group_id="O2" value="83.7" lower_limit="81" upper_limit="86.1"/>
                    <measurement group_id="O3" value="78.8" lower_limit="75.9" upper_limit="81.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.4" lower_limit="94.8" upper_limit="97.6"/>
                    <measurement group_id="O2" value="92.3" lower_limit="90.2" upper_limit="94"/>
                    <measurement group_id="O3" value="89.8" lower_limit="87.5" upper_limit="91.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.5" lower_limit="96.1" upper_limit="98.5"/>
                    <measurement group_id="O2" value="86.4" lower_limit="83.9" upper_limit="88.7"/>
                    <measurement group_id="O3" value="84.5" lower_limit="81.8" upper_limit="86.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>superiority was concluded if the lower limit of the confidence interval of day 50 vaccine group difference,for at least 2 homologous strains, was &gt;10%</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Group difference (H1N1 strain)</param_type>
            <param_value>9.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>6.3</ci_lower_limit>
            <ci_upper_limit>12.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>superiority was concluded if the lower limit of the confidence interval of day 50 vaccine group difference,for at least 2 homologous strains, was &gt;10%</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Group difference (H3N2 strain)</param_type>
            <param_value>3.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.8</ci_lower_limit>
            <ci_upper_limit>5.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>superiority was concluded if the lower limit of the confidence interval of day 50 vaccine group difference,for at least 2 homologous strains, was &gt;10%</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Group difference (B strain)</param_type>
            <param_value>10.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>8.1</ci_lower_limit>
            <ci_upper_limit>13.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>superiority was concluded if the lower limit of the confidence interval of day 50 vaccine group difference,for at least 2 homologous strains, was &gt;10%</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Group difference (H1N1 strain)</param_type>
            <param_value>14.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>11.1</ci_lower_limit>
            <ci_upper_limit>17.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>superiority was concluded if the lower bound of 95% CI of day 50 vaccine group difference,for at least 2 homologous strains, was &gt;10%</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Group difference (H3N2 strain)</param_type>
            <param_value>6.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.5</ci_lower_limit>
            <ci_upper_limit>9.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>superiority was concluded if the lower limit of the confidence interval of day 50 vaccine group difference,for at least 2 homologous strains, was &gt;10%</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Group difference (B strain)</param_type>
            <param_value>10.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>8.3</ci_lower_limit>
            <ci_upper_limit>13.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The HI GMTs Against Homologous Strains, by Vaccine Group</title>
        <description>The HI antibody titers against the three homologous strains following vaccination with either aTIV, licensed comparator or TIV, at three weeks and at six months after vaccination are reported as GMTs.</description>
        <time_frame>Day 1, Day 29, Day 50, Day 209</time_frame>
        <population>Analysis was done on FAS (Persistence) i.e. all subjects in the enrolled population who actually received a study vaccination, and provided evaluable serum samples at all relevant timepoints and also at day 209.</population>
        <group_list>
          <group group_id="O1">
            <title>aTIV (6 to &lt;72 Months)</title>
            <description>Subjects received an investigational MF59-adjuvanted trivalent influenza vaccine (aTIV), subjects aged between 6 to &lt;36 months received two doses of 0.25 mL each, while subjects aged ≥36 months received two doses of 0.5 mL each, at Days 1 &amp; 29</description>
          </group>
          <group group_id="O2">
            <title>Comparator TIV (6 to &lt;72 Months)</title>
            <description>Subjects received a licensed comparator trivalent split influenza vaccine (comparator TIV), subjects aged between 6 to &lt;36 months received two doses of 0.25 mL each, while subjects aged ≥36 months received two doses of 0.5 mL each, at Days 1 &amp; 29</description>
          </group>
          <group group_id="O3">
            <title>TIV (6 to &lt;72 Months)</title>
            <description>Subjects received an investigational trivalent split influenza vaccine (TIV), subjects aged between 6 to &lt;36 months received two doses of 0.25 mL each, while subjects aged ≥36 months received two doses of 0.5 mL each, at Days 1 &amp; 29</description>
          </group>
        </group_list>
        <measure>
          <title>The HI GMTs Against Homologous Strains, by Vaccine Group</title>
          <description>The HI antibody titers against the three homologous strains following vaccination with either aTIV, licensed comparator or TIV, at three weeks and at six months after vaccination are reported as GMTs.</description>
          <population>Analysis was done on FAS (Persistence) i.e. all subjects in the enrolled population who actually received a study vaccination, and provided evaluable serum samples at all relevant timepoints and also at day 209.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="715"/>
                <count group_id="O2" value="822"/>
                <count group_id="O3" value="820"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1 - Day 1 (N=714,822,820)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28" lower_limit="24" upper_limit="32"/>
                    <measurement group_id="O2" value="24" lower_limit="20" upper_limit="27"/>
                    <measurement group_id="O3" value="27" lower_limit="23" upper_limit="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H1N1 - Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="647" lower_limit="562" upper_limit="745"/>
                    <measurement group_id="O2" value="159" lower_limit="139" upper_limit="182"/>
                    <measurement group_id="O3" value="170" lower_limit="148" upper_limit="194"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H1N1 - Day 50 (N=714,822,820)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1507" lower_limit="1358" upper_limit="1673"/>
                    <measurement group_id="O2" value="635" lower_limit="575" upper_limit="702"/>
                    <measurement group_id="O3" value="475" lower_limit="429" upper_limit="525"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H1N1 - Day 209 (N=715,822,819)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="276" lower_limit="246" upper_limit="311"/>
                    <measurement group_id="O2" value="97" lower_limit="87" upper_limit="109"/>
                    <measurement group_id="O3" value="107" lower_limit="96" upper_limit="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2 - Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42" lower_limit="36" upper_limit="48"/>
                    <measurement group_id="O2" value="43" lower_limit="37" upper_limit="49"/>
                    <measurement group_id="O3" value="43" lower_limit="38" upper_limit="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2 - Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1087" lower_limit="1004" upper_limit="1176"/>
                    <measurement group_id="O2" value="558" lower_limit="517" upper_limit="602"/>
                    <measurement group_id="O3" value="453" lower_limit="420" upper_limit="490"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2 - Day 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1920" lower_limit="1799" upper_limit="2050"/>
                    <measurement group_id="O2" value="1013" lower_limit="952" upper_limit="1079"/>
                    <measurement group_id="O3" value="810" lower_limit="760" upper_limit="862"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2 - Day 209</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="462" lower_limit="423" upper_limit="505"/>
                    <measurement group_id="O2" value="277" lower_limit="254" upper_limit="301"/>
                    <measurement group_id="O3" value="242" lower_limit="222" upper_limit="263"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B - Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" lower_limit="9.29" upper_limit="11"/>
                    <measurement group_id="O2" value="10" lower_limit="9.57" upper_limit="11"/>
                    <measurement group_id="O3" value="10" lower_limit="9.34" upper_limit="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B - Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="119" lower_limit="106" upper_limit="134"/>
                    <measurement group_id="O2" value="58" lower_limit="52" upper_limit="65"/>
                    <measurement group_id="O3" value="61" lower_limit="54" upper_limit="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B - Day 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="488" lower_limit="447" upper_limit="532"/>
                    <measurement group_id="O2" value="166" lower_limit="153" upper_limit="180"/>
                    <measurement group_id="O3" value="159" lower_limit="146" upper_limit="173"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B- Day 209</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="125" lower_limit="114" upper_limit="136"/>
                    <measurement group_id="O2" value="57" lower_limit="53" upper_limit="62"/>
                    <measurement group_id="O3" value="61" lower_limit="56" upper_limit="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Ratio (GMR) of Post- Versus Pre-vaccination HI Titers Against Homologous Strains</title>
        <description>The GMR of post-vaccination versus pre-vaccination HI titers against homologous strains, three weeks (day 29/day 1; day 50/day 1)and six months (day 209/day 1) after vaccination with either aTIV, licensed comparator or TIV.</description>
        <time_frame>Day 29, Day 50, Day 209</time_frame>
        <population>Analysis was done on FAS (Persistence)</population>
        <group_list>
          <group group_id="O1">
            <title>aTIV (6 to &lt;72 Months)</title>
            <description>Subjects received an investigational MF59-adjuvanted trivalent influenza vaccine (aTIV), subjects aged between 6 to &lt;36 months received two doses of 0.25 mL each, while subjects aged ≥36 months received two doses of 0.5 mL each, at Days 1 &amp; 29</description>
          </group>
          <group group_id="O2">
            <title>Comparator TIV (6 to &lt;72 Months)</title>
            <description>Subjects received a licensed comparator trivalent split influenza vaccine (comparator TIV), subjects aged between 6 to &lt;36 months received two doses of 0.25 mL each, while subjects aged ≥36 months received two doses of 0.5 mL each, at Days 1 &amp; 29</description>
          </group>
          <group group_id="O3">
            <title>TIV (6 to &lt;72 Months)</title>
            <description>Subjects received an investigational trivalent split influenza vaccine (TIV), subjects aged between 6 to &lt;36 months received two doses of 0.25 mL each, while subjects aged ≥36 months received two doses of 0.5 mL each, at Days 1 &amp; 29</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Ratio (GMR) of Post- Versus Pre-vaccination HI Titers Against Homologous Strains</title>
          <description>The GMR of post-vaccination versus pre-vaccination HI titers against homologous strains, three weeks (day 29/day 1; day 50/day 1)and six months (day 209/day 1) after vaccination with either aTIV, licensed comparator or TIV.</description>
          <population>Analysis was done on FAS (Persistence)</population>
          <units>Ratios</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="715"/>
                <count group_id="O2" value="822"/>
                <count group_id="O3" value="820"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1, Day 29:Day 1 (N=714,822,820)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27" lower_limit="23" upper_limit="31"/>
                    <measurement group_id="O2" value="6.81" lower_limit="5.94" upper_limit="7.81"/>
                    <measurement group_id="O3" value="7.13" lower_limit="6.22" upper_limit="8.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H1N1, Day 50:Day 1 (N=713,822,820)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58" lower_limit="51" upper_limit="67"/>
                    <measurement group_id="O2" value="27" lower_limit="24" upper_limit="31"/>
                    <measurement group_id="O3" value="19" lower_limit="17" upper_limit="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H1N1, Day 209:Day 1 (N=714,822,819)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11" lower_limit="9.79" upper_limit="13"/>
                    <measurement group_id="O2" value="4.15" lower_limit="3.68" upper_limit="4.69"/>
                    <measurement group_id="O3" value="4.37" lower_limit="3.87" upper_limit="4.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2, Day 29:Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29" lower_limit="26" upper_limit="32"/>
                    <measurement group_id="O2" value="15" lower_limit="14" upper_limit="16"/>
                    <measurement group_id="O3" value="12" lower_limit="11" upper_limit="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2, Day 50:Day 1 (N=715,822,820)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48" lower_limit="43" upper_limit="54"/>
                    <measurement group_id="O2" value="25" lower_limit="23" upper_limit="28"/>
                    <measurement group_id="O3" value="20" lower_limit="18" upper_limit="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2, Day 209:Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12" lower_limit="10" upper_limit="13"/>
                    <measurement group_id="O2" value="6.93" lower_limit="6.14" upper_limit="7.83"/>
                    <measurement group_id="O3" value="6.02" lower_limit="5.33" upper_limit="6.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B strain, Day 29:Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12" lower_limit="11" upper_limit="14"/>
                    <measurement group_id="O2" value="6.18" lower_limit="5.49" upper_limit="6.95"/>
                    <measurement group_id="O3" value="6.38" lower_limit="5.66" upper_limit="7.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B strain, Day 50:Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49" lower_limit="45" upper_limit="54"/>
                    <measurement group_id="O2" value="17" lower_limit="15" upper_limit="18"/>
                    <measurement group_id="O3" value="16" lower_limit="15" upper_limit="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B strain, Day 209:Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13" lower_limit="12" upper_limit="14"/>
                    <measurement group_id="O2" value="5.76" lower_limit="5.26" upper_limit="6.3"/>
                    <measurement group_id="O3" value="6.15" lower_limit="5.62" upper_limit="6.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With HI Titers ≥40 Against Homologous Strains, by Vaccine Group</title>
        <description>The percentage of subjects demonstrating HI titers ≥40,against homologous strains, at three weeks and six months after vaccination with aTIV or licensed comparator or TIV.</description>
        <time_frame>Day 1, Day 29, Day 50, Day 209</time_frame>
        <population>Analysis was done on FAS (Persistence)</population>
        <group_list>
          <group group_id="O1">
            <title>aTIV (6 to &lt;72 Months)</title>
            <description>Subjects received an investigational MF59-adjuvanted trivalent influenza vaccine (aTIV), subjects aged between 6 to &lt;36 months received two doses of 0.25 mL each, while subjects aged ≥36 months received two doses of 0.5 mL each, at Days 1 &amp; 29</description>
          </group>
          <group group_id="O2">
            <title>Comparator TIV (6 to &lt;72 Months)</title>
            <description>Subjects received a licensed comparator trivalent split influenza vaccine (comparator TIV), subjects aged between 6 to &lt;36 months received two doses of 0.25 mL each, while subjects aged ≥36 months received two doses of 0.5 mL each, at Days 1 &amp; 29</description>
          </group>
          <group group_id="O3">
            <title>TIV (6 to &lt;72 Months)</title>
            <description>Subjects received an investigational trivalent split influenza vaccine (TIV), subjects aged between 6 to &lt;36 months received two doses of 0.25 mL each, while subjects aged ≥36 months received two doses of 0.5 mL each, at Days 1 &amp; 29</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With HI Titers ≥40 Against Homologous Strains, by Vaccine Group</title>
          <description>The percentage of subjects demonstrating HI titers ≥40,against homologous strains, at three weeks and six months after vaccination with aTIV or licensed comparator or TIV.</description>
          <population>Analysis was done on FAS (Persistence)</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="715"/>
                <count group_id="O2" value="822"/>
                <count group_id="O3" value="820"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1, Day 1 (N=714,822,820)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.6" lower_limit="37" upper_limit="44.3"/>
                    <measurement group_id="O2" value="33.1" lower_limit="29.9" upper_limit="36.4"/>
                    <measurement group_id="O3" value="36.3" lower_limit="33" upper_limit="39.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H1N1, Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.8" lower_limit="87.3" upper_limit="91.9"/>
                    <measurement group_id="O2" value="55" lower_limit="51.5" upper_limit="58.4"/>
                    <measurement group_id="O3" value="57.9" lower_limit="54.5" upper_limit="61.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H1N1, Day 50 (N=714,822,820)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.3" lower_limit="98.4" upper_limit="99.8"/>
                    <measurement group_id="O2" value="91.1" lower_limit="89" upper_limit="93"/>
                    <measurement group_id="O3" value="88.2" lower_limit="85.8" upper_limit="90.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H1N1, Day 209 (N=715, 822,819)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.8" lower_limit="86.3" upper_limit="91"/>
                    <measurement group_id="O2" value="59.5" lower_limit="56" upper_limit="62.9"/>
                    <measurement group_id="O3" value="63.2" lower_limit="59.8" upper_limit="66.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2, Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.6" lower_limit="48.9" upper_limit="56.3"/>
                    <measurement group_id="O2" value="45.5" lower_limit="42.1" upper_limit="49"/>
                    <measurement group_id="O3" value="44.6" lower_limit="41.2" upper_limit="48.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2, Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.9" lower_limit="97.8" upper_limit="99.5"/>
                    <measurement group_id="O2" value="95.9" lower_limit="94.3" upper_limit="97.1"/>
                    <measurement group_id="O3" value="93.5" lower_limit="91.6" upper_limit="95.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2, Day 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.7" lower_limit="99" upper_limit="100"/>
                    <measurement group_id="O2" value="99.5" lower_limit="98.8" upper_limit="99.9"/>
                    <measurement group_id="O3" value="99.4" lower_limit="98.6" upper_limit="99.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2, Day 209</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.3" lower_limit="98.4" upper_limit="99.8"/>
                    <measurement group_id="O2" value="94.3" lower_limit="92.5" upper_limit="95.8"/>
                    <measurement group_id="O3" value="88.4" lower_limit="86" upper_limit="90.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B strain, Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.1" lower_limit="19.1" upper_limit="25.3"/>
                    <measurement group_id="O2" value="21.1" lower_limit="18.3" upper_limit="24"/>
                    <measurement group_id="O3" value="20.5" lower_limit="17.8" upper_limit="23.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B strain, Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69" lower_limit="65.4" upper_limit="72.3"/>
                    <measurement group_id="O2" value="48.2" lower_limit="44.7" upper_limit="51.7"/>
                    <measurement group_id="O3" value="45.6" lower_limit="42.2" upper_limit="49.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B strain, Day 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.9" lower_limit="97.8" upper_limit="99.5"/>
                    <measurement group_id="O2" value="89.1" lower_limit="86.7" upper_limit="91.1"/>
                    <measurement group_id="O3" value="87" lower_limit="84.5" upper_limit="89.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B strain, Day 209</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.4" lower_limit="91.4" upper_limit="95.1"/>
                    <measurement group_id="O2" value="67.9" lower_limit="64.6" upper_limit="71.1"/>
                    <measurement group_id="O3" value="67" lower_limit="63.6" upper_limit="70.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects Achieving Seroconversion or ≥4 Fold Increase in HI Titers, Against Homologous Strains</title>
        <description>The percentage of subjects achieving seroconversion ≥4 fold increase in HI titers from baseline, against homologous strains, at three weeks and six months after vaccination with ATIV or licensed comparator or TIV.</description>
        <time_frame>Day 29, Day 50, Day 209</time_frame>
        <population>Analysis was done on FAS (Persistence)</population>
        <group_list>
          <group group_id="O1">
            <title>aTIV (6 to &lt;72 Months)</title>
            <description>Subjects received an investigational MF59-adjuvanted trivalent influenza vaccine (aTIV), subjects aged between 6 to &lt;36 months received two doses of 0.25 mL each, while subjects aged ≥36 months received two doses of 0.5 mL each, at Days 1 &amp; 29</description>
          </group>
          <group group_id="O2">
            <title>Comparator TIV (6 to &lt;72 Months)</title>
            <description>Subjects received a licensed comparator trivalent split influenza vaccine (comparator TIV), subjects aged between 6 to &lt;36 months received two doses of 0.25 mL each, while subjects aged ≥36 months received two doses of 0.5 mL each, at Days 1 &amp; 29</description>
          </group>
          <group group_id="O3">
            <title>TIV (6 to &lt;72 Months)</title>
            <description>Subjects received an investigational trivalent split influenza vaccine (TIV), subjects aged between 6 to &lt;36 months received two doses of 0.25 mL each, while subjects aged ≥36 months received two doses of 0.5 mL each, at Days 1 &amp; 29</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Achieving Seroconversion or ≥4 Fold Increase in HI Titers, Against Homologous Strains</title>
          <description>The percentage of subjects achieving seroconversion ≥4 fold increase in HI titers from baseline, against homologous strains, at three weeks and six months after vaccination with ATIV or licensed comparator or TIV.</description>
          <population>Analysis was done on FAS (Persistence)</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="715"/>
                <count group_id="O2" value="822"/>
                <count group_id="O3" value="820"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1, Day 29 (N=714,822,820)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.6" lower_limit="80.7" upper_limit="86.3"/>
                    <measurement group_id="O2" value="48.5" lower_limit="45.1" upper_limit="52.1"/>
                    <measurement group_id="O3" value="51.5" lower_limit="48" upper_limit="54.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H1N1, Day 50 (N=713,822,820)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.6" lower_limit="90.4" upper_limit="94.4"/>
                    <measurement group_id="O2" value="83.9" lower_limit="81.3" upper_limit="86.4"/>
                    <measurement group_id="O3" value="79" lower_limit="76.1" upper_limit="81.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H1N1, Day 209 (N=714,822,819)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.7" lower_limit="68.3" upper_limit="75"/>
                    <measurement group_id="O2" value="39.5" lower_limit="36.2" upper_limit="43"/>
                    <measurement group_id="O3" value="41.9" lower_limit="38.5" upper_limit="45.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2, Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.8" lower_limit="94.1" upper_limit="97.2"/>
                    <measurement group_id="O2" value="90.3" lower_limit="88" upper_limit="92.2"/>
                    <measurement group_id="O3" value="86.7" lower_limit="84.2" upper_limit="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2, Day 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.5" lower_limit="94.9" upper_limit="97.7"/>
                    <measurement group_id="O2" value="92.1" lower_limit="90" upper_limit="93.8"/>
                    <measurement group_id="O3" value="90" lower_limit="87.7" upper_limit="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2, Day 209</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.6" lower_limit="74.4" upper_limit="80.6"/>
                    <measurement group_id="O2" value="62.5" lower_limit="59.1" upper_limit="65.9"/>
                    <measurement group_id="O3" value="55.6" lower_limit="52.1" upper_limit="59.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B strain, Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.4" lower_limit="64.8" upper_limit="71.8"/>
                    <measurement group_id="O2" value="47" lower_limit="43.5" upper_limit="50.4"/>
                    <measurement group_id="O3" value="44" lower_limit="40.6" upper_limit="47.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B strain, Day 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.6" lower_limit="96.2" upper_limit="98.6"/>
                    <measurement group_id="O2" value="86.6" lower_limit="84.1" upper_limit="88.9"/>
                    <measurement group_id="O3" value="85" lower_limit="82.4" upper_limit="87.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B strain, Day 209</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.3" lower_limit="84.6" upper_limit="89.6"/>
                    <measurement group_id="O2" value="59.7" lower_limit="56.3" upper_limit="63.1"/>
                    <measurement group_id="O3" value="61.5" lower_limit="58" upper_limit="64.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparison of Antibody Responses of aTIV With TIV and Comparator TIV in Terms of GMTs Against Homologous Strains, Subjects at Risk/Not at Risk, by Age Subgroup</title>
        <description>The non-inferiority of Hemagglutination Inhibition (HI) antibody responses of aTIV compared to TIV and comparator TIV assessed in terms of post vaccination GMTs at three weeks after last vaccination against the three homologous vaccine strains, in subjects with a defined set of underlying medical conditions (at risk) and healthy subjects (not at risk), by age sub group.</description>
        <time_frame>Day 50</time_frame>
        <population>Analysis was done on the PPS.</population>
        <group_list>
          <group group_id="O1">
            <title>aTIV (6 to &lt;72 Months)</title>
            <description>Subjects received an investigational MF59-adjuvanted trivalent influenza vaccine (aTIV), subjects aged between 6 to &lt;36 months received two doses (Day 1 &amp; 29) while subjects aged ≥36 months received one dose (at Day 1) of the vaccine</description>
          </group>
          <group group_id="O2">
            <title>Compartor TIV (6 to &lt;72 Months)</title>
            <description>Subjects received a licensed comparator trivalent split influenza vaccine (comparator TIV), subjects aged between 6 to &lt;36 months received two doses (Day 1 &amp; 29) while subjects aged ≥36 months received one dose (at Day 1) of the vaccine</description>
          </group>
          <group group_id="O3">
            <title>TIV (6 to &lt;72 Months)</title>
            <description>Subjects received an investigational trivalent split influenza vaccine (TIV), subjects aged between 6 to &lt;36 months received two doses (Day 1 &amp; 29) while subjects aged ≥36 months received one dose (Day 1) of the vaccine</description>
          </group>
          <group group_id="O4">
            <title>aTIV (6 to &lt;36 Months)</title>
            <description>Subjects received two doses (Day 1 &amp; 29) of an investigational MF59-adjuvanted trivalent influenza vaccine (aTIV)</description>
          </group>
          <group group_id="O5">
            <title>Compartor TIV (6 to &lt;36 Months)</title>
            <description>Subjects received two doses (Day 1 &amp; 29) of a licensed comparator trivalent split influenza vaccine (comparator TIV)</description>
          </group>
          <group group_id="O6">
            <title>TIV (6 to &lt;36 Months)</title>
            <description>Subjects received two doses (Day 1 &amp; 29) of an investigational trivalent split influenza vaccine (TIV)</description>
          </group>
          <group group_id="O7">
            <title>aTIV (36 to &lt;72 Months)</title>
            <description>Subjects received one dose (Day 1) of investigational MF59-adjuvanted trivalent influenza vaccine (aTIV)</description>
          </group>
          <group group_id="O8">
            <title>Comparator TIV (36 to &lt;72 Months)</title>
            <description>Subjects received one dose (Day 1) of a licensed comparator trivalent split influenza vaccine (comparator TIV)</description>
          </group>
          <group group_id="O9">
            <title>TIV (36 to &lt;72 Months)</title>
            <description>Subjects received one dose (Day 1) of an investigational trivalent split influenza vaccine (TIV)</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of Antibody Responses of aTIV With TIV and Comparator TIV in Terms of GMTs Against Homologous Strains, Subjects at Risk/Not at Risk, by Age Subgroup</title>
          <description>The non-inferiority of Hemagglutination Inhibition (HI) antibody responses of aTIV compared to TIV and comparator TIV assessed in terms of post vaccination GMTs at three weeks after last vaccination against the three homologous vaccine strains, in subjects with a defined set of underlying medical conditions (at risk) and healthy subjects (not at risk), by age sub group.</description>
          <population>Analysis was done on the PPS.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="660"/>
                <count group_id="O2" value="722"/>
                <count group_id="O3" value="739"/>
                <count group_id="O4" value="425"/>
                <count group_id="O5" value="612"/>
                <count group_id="O6" value="623"/>
                <count group_id="O7" value="235"/>
                <count group_id="O8" value="110"/>
                <count group_id="O9" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1nonrisk(N=659,722,739,425,612,623,234,110,116)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1516" lower_limit="1358" upper_limit="1692"/>
                    <measurement group_id="O2" value="566" lower_limit="509" upper_limit="628"/>
                    <measurement group_id="O3" value="431" lower_limit="388" upper_limit="478"/>
                    <measurement group_id="O4" value="1341" lower_limit="1165" upper_limit="1544"/>
                    <measurement group_id="O5" value="478" lower_limit="425" upper_limit="537"/>
                    <measurement group_id="O6" value="366" lower_limit="326" upper_limit="411"/>
                    <measurement group_id="O7" value="2111" lower_limit="1840" upper_limit="2423"/>
                    <measurement group_id="O8" value="1365" lower_limit="1117" upper_limit="1668"/>
                    <measurement group_id="O9" value="879" lower_limit="723" upper_limit="1068"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2nonrisk(N=660,722,739,425,612,623,235,110,116)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1897" lower_limit="1772" upper_limit="2030"/>
                    <measurement group_id="O2" value="1014" lower_limit="950" upper_limit="1082"/>
                    <measurement group_id="O3" value="804" lower_limit="754" upper_limit="857"/>
                    <measurement group_id="O4" value="1863" lower_limit="1711" upper_limit="2028"/>
                    <measurement group_id="O5" value="912" lower_limit="849" upper_limit="979"/>
                    <measurement group_id="O6" value="695" lower_limit="648" upper_limit="746"/>
                    <measurement group_id="O7" value="2311" lower_limit="2080" upper_limit="2568"/>
                    <measurement group_id="O8" value="1526" lower_limit="1309" upper_limit="1780"/>
                    <measurement group_id="O9" value="1497" lower_limit="1289" upper_limit="1739"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B nonrisk(N=660,722,739,425,612,623,235,110,116)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="492" lower_limit="450" upper_limit="539"/>
                    <measurement group_id="O2" value="162" lower_limit="148" upper_limit="176"/>
                    <measurement group_id="O3" value="157" lower_limit="144" upper_limit="170"/>
                    <measurement group_id="O4" value="559" lower_limit="498" upper_limit="627"/>
                    <measurement group_id="O5" value="149" lower_limit="136" upper_limit="164"/>
                    <measurement group_id="O6" value="141" lower_limit="128" upper_limit="155"/>
                    <measurement group_id="O7" value="431" lower_limit="380" upper_limit="488"/>
                    <measurement group_id="O8" value="226" lower_limit="188" upper_limit="272"/>
                    <measurement group_id="O9" value="254" lower_limit="212" upper_limit="304"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H1N1 at risk(N=22,35,26,12,23,19,10,12,7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1706" lower_limit="990" upper_limit="2939"/>
                    <measurement group_id="O2" value="772" lower_limit="502" upper_limit="1185"/>
                    <measurement group_id="O3" value="631" lower_limit="383" upper_limit="1041"/>
                    <measurement group_id="O4" value="1414" lower_limit="658" upper_limit="3040"/>
                    <measurement group_id="O5" value="603" lower_limit="350" upper_limit="1040"/>
                    <measurement group_id="O6" value="519" lower_limit="283" upper_limit="950"/>
                    <measurement group_id="O7" value="2187" lower_limit="956" upper_limit="5002"/>
                    <measurement group_id="O8" value="1241" lower_limit="583" upper_limit="2641"/>
                    <measurement group_id="O9" value="1030" lower_limit="383" upper_limit="2767"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2 at risk(N=22,35,26,12,23,19,10,12,7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2306" lower_limit="1665" upper_limit="3194"/>
                    <measurement group_id="O2" value="941" lower_limit="727" upper_limit="1220"/>
                    <measurement group_id="O3" value="709" lower_limit="526" upper_limit="955"/>
                    <measurement group_id="O4" value="2323" lower_limit="1407" upper_limit="3835"/>
                    <measurement group_id="O5" value="794" lower_limit="552" upper_limit="1140"/>
                    <measurement group_id="O6" value="665" lower_limit="447" upper_limit="988"/>
                    <measurement group_id="O7" value="2319" lower_limit="1622" upper_limit="3315"/>
                    <measurement group_id="O8" value="1306" lower_limit="940" upper_limit="1815"/>
                    <measurement group_id="O9" value="826" lower_limit="538" upper_limit="1267"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B at risk(N=22,35,26,12,23,19,10,12,7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="495" lower_limit="307" upper_limit="797"/>
                    <measurement group_id="O2" value="143" lower_limit="98" upper_limit="209"/>
                    <measurement group_id="O3" value="179" lower_limit="116" upper_limit="278"/>
                    <measurement group_id="O4" value="694" lower_limit="367" upper_limit="1316"/>
                    <measurement group_id="O5" value="125" lower_limit="79" upper_limit="199"/>
                    <measurement group_id="O6" value="132" lower_limit="79" upper_limit="220"/>
                    <measurement group_id="O7" value="365" lower_limit="184" upper_limit="724"/>
                    <measurement group_id="O8" value="200" lower_limit="108" upper_limit="372"/>
                    <measurement group_id="O9" value="312" lower_limit="131" upper_limit="743"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>No risk subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Noninferiority was concluded if the lower limit of the 2-sided 97.6% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.</non_inferiority_desc>
            <param_type>GMT Ratio (H1N1 strain)</param_type>
            <param_value>2.68</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.3</ci_lower_limit>
            <ci_upper_limit>3.12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>No risk subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Noninferiority was concluded if the lower limit of the 2-sided 97.6% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.</non_inferiority_desc>
            <param_type>GMT Ratio (H3N2 strain)</param_type>
            <param_value>1.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.7</ci_lower_limit>
            <ci_upper_limit>2.05</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>No risk subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Noninferiority was concluded if the lower limit of the 2-sided 97.6% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.</non_inferiority_desc>
            <param_type>GMT ratio (B strain)</param_type>
            <param_value>3.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.68</ci_lower_limit>
            <ci_upper_limit>3.44</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>At risk subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Noninferiority was concluded if the lower limit of the 2-sided 97.6% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.</non_inferiority_desc>
            <param_type>GMT ratio (H1N1 strain)</param_type>
            <param_value>2.21</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.11</ci_lower_limit>
            <ci_upper_limit>4.42</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>At risk subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Noninferiority was concluded if the lower limit of the 2-sided 97.6% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.</non_inferiority_desc>
            <param_type>GMT ratio (H3N2 strain)</param_type>
            <param_value>2.45</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.61</ci_lower_limit>
            <ci_upper_limit>3.72</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>At risk subjects</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Noninferiority was concluded if the lower limit of the 2-sided 97.6% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.</non_inferiority_desc>
            <param_type>GMT ratio (B strain)</param_type>
            <param_value>3.46</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.88</ci_lower_limit>
            <ci_upper_limit>6.34</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>No risk subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Noninferiority was concluded if the lower limit of the 2-sided 97.6% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.</non_inferiority_desc>
            <param_type>GMT ratios (H1N1 strain)</param_type>
            <param_value>3.52</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.03</ci_lower_limit>
            <ci_upper_limit>4.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>No risk subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Noninferiority was concluded if the lower limit of the 2-sided 97.6% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.</non_inferiority_desc>
            <param_type>GMT ratio (H3N2 strain)</param_type>
            <param_value>2.36</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.15</ci_lower_limit>
            <ci_upper_limit>2.59</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>No risk subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Noninferiority was concluded if the lower limit of the 2-sided 97.6% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.</non_inferiority_desc>
            <param_type>GMT ratio (B strain)</param_type>
            <param_value>3.14</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.78</ci_lower_limit>
            <ci_upper_limit>3.56</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>At risk subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Noninferiority was concluded if the lower limit of the 2-sided 97.6% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.</non_inferiority_desc>
            <param_type>GMT ratio (H1N1 strain)</param_type>
            <param_value>2.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.28</ci_lower_limit>
            <ci_upper_limit>5.68</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>At risk subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Noninferiority was concluded if the lower limit of the 2-sided 97.6% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.</non_inferiority_desc>
            <param_type>GMT ratio (H3N2 strain)</param_type>
            <param_value>3.25</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.09</ci_lower_limit>
            <ci_upper_limit>5.06</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>At risk subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Noninferiority was concluded if the lower limit of the 2-sided 97.6% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.</non_inferiority_desc>
            <param_type>GMT ratio (B strain)</param_type>
            <param_value>2.76</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.44</ci_lower_limit>
            <ci_upper_limit>5.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>No risk subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Noninferiority was concluded if the lower limit of the 2-sided 97.6% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.</non_inferiority_desc>
            <param_type>GMT ratio (H1N1 strain)</param_type>
            <param_value>2.81</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.34</ci_lower_limit>
            <ci_upper_limit>3.37</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>No risk subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Noninferiority was concluded if the lower limit of the 2-sided 97.6% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.</non_inferiority_desc>
            <param_type>GMT ratio (H3N2 strain)</param_type>
            <param_value>2.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.83</ci_lower_limit>
            <ci_upper_limit>2.28</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>No risk subjects</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Noninferiority was concluded if the lower limit of the 2-sided 97.6% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.</non_inferiority_desc>
            <param_type>GMT ratio (B strain)</param_type>
            <param_value>3.74</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.22</ci_lower_limit>
            <ci_upper_limit>4.34</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>At risk subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Noninferiority was concluded if the lower limit of the 2-sided 97.6% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.</non_inferiority_desc>
            <param_type>GMT ratio (H1N1 strain)</param_type>
            <param_value>2.34</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.92</ci_lower_limit>
            <ci_upper_limit>6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>At risk subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Noninferiority was concluded if the lower limit of the 2-sided 97.6% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.</non_inferiority_desc>
            <param_type>GMT ratio (H3N2 strain)</param_type>
            <param_value>2.93</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.57</ci_lower_limit>
            <ci_upper_limit>5.45</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>At risk subjects</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Noninferiority was concluded if the lower limit of the 2-sided 97.6% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.</non_inferiority_desc>
            <param_type>GMT ratio (B strain)</param_type>
            <param_value>5.55</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.52</ci_lower_limit>
            <ci_upper_limit>12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>No risk subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Noninferiority was concluded if the lower limit of the 2-sided 97.6% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.</non_inferiority_desc>
            <param_type>GMT ratio (H1N1 strain)</param_type>
            <param_value>3.66</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.05</ci_lower_limit>
            <ci_upper_limit>4.39</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>No risk subjects</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Noninferiority was concluded if the lower limit of the 2-sided 97.6% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.</non_inferiority_desc>
            <param_type>GMT ratio (H3N2 strain)</param_type>
            <param_value>2.68</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.4</ci_lower_limit>
            <ci_upper_limit>2.99</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>No risk subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Noninferiority was concluded if the lower limit of the 2-sided 97.6% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.</non_inferiority_desc>
            <param_type>GMT ratio (B strain)</param_type>
            <param_value>3.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.42</ci_lower_limit>
            <ci_upper_limit>4.61</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>At risk subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Noninferiority was concluded if the lower limit of the 2-sided 97.6% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.</non_inferiority_desc>
            <param_type>GMT ratio (H1N1 strain)</param_type>
            <param_value>2.72</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.02</ci_lower_limit>
            <ci_upper_limit>7.31</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>At risk subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Noninferiority was concluded if the lower limit of the 2-sided 97.6% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.</non_inferiority_desc>
            <param_type>GMT ratio (H3N2 strain)</param_type>
            <param_value>3.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.85</ci_lower_limit>
            <ci_upper_limit>6.62</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>At risk subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Noninferiority was concluded if the lower limit of the 2-sided 97.6% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.</non_inferiority_desc>
            <param_type>GMT ratio (B strain)</param_type>
            <param_value>5.26</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.32</ci_lower_limit>
            <ci_upper_limit>12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>No risk subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Noninferiority was concluded if the lower limit of the 2-sided 97.6% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.</non_inferiority_desc>
            <param_type>GMT ratio (H1N1 strain)</param_type>
            <param_value>1.55</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.21</ci_lower_limit>
            <ci_upper_limit>1.97</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>No risk subjects</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Noninferiority was concluded if the lower limit of the 2-sided 97.6% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.</non_inferiority_desc>
            <param_type>GMT ratio (H3N2 strain)</param_type>
            <param_value>1.51</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.26</ci_lower_limit>
            <ci_upper_limit>1.82</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>No risk subjects</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Noninferiority was concluded if the lower limit of the 2-sided 97.6% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.</non_inferiority_desc>
            <param_type>GMT ratio (B strain)</param_type>
            <param_value>1.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.52</ci_lower_limit>
            <ci_upper_limit>2.38</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>At risk subjects</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Noninferiority was concluded if the lower limit of the 2-sided 97.6% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.</non_inferiority_desc>
            <param_type>GMT ratio (H1N1 strain)</param_type>
            <param_value>1.76</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.57</ci_lower_limit>
            <ci_upper_limit>5.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>At risk subjects</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Noninferiority was concluded if the lower limit of the 2-sided 97.6% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.</non_inferiority_desc>
            <param_type>GMT ratio (H3N2 strain)</param_type>
            <param_value>1.78</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.09</ci_lower_limit>
            <ci_upper_limit>2.89</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>At risk subjects</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Noninferiority was concluded if the lower limit of the 2-sided 97.6% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.</non_inferiority_desc>
            <param_type>GMT ratio (B strain)</param_type>
            <param_value>1.82</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.73</ci_lower_limit>
            <ci_upper_limit>4.54</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>No risk subjects</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Noninferiority was concluded if the lower limit of the 2-sided 97.6% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.</non_inferiority_desc>
            <param_type>GMT ratio (H1N1 strain)</param_type>
            <param_value>2.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.89</ci_lower_limit>
            <ci_upper_limit>3.05</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>No risk subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Noninferiority was concluded if the lower limit of the 2-sided 97.6% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.</non_inferiority_desc>
            <param_type>GMT ratio (H3N2 strain)</param_type>
            <param_value>1.54</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.29</ci_lower_limit>
            <ci_upper_limit>1.85</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>No risk subjects</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Noninferiority was concluded if the lower limit of the 2-sided 97.6% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.</non_inferiority_desc>
            <param_type>GMT ratio (B strain)</param_type>
            <param_value>1.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.36</ci_lower_limit>
            <ci_upper_limit>2.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>At risk subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Noninferiority was concluded if the lower limit of the 2-sided 97.6% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.</non_inferiority_desc>
            <param_type>GMT ratio (H1N1 strain)</param_type>
            <param_value>2.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.58</ci_lower_limit>
            <ci_upper_limit>7.71</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>At risk subjects</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Noninferiority was concluded if the lower limit of the 2-sided 97.6% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.</non_inferiority_desc>
            <param_type>GMT ratio (H3N2 strain)</param_type>
            <param_value>2.81</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.61</ci_lower_limit>
            <ci_upper_limit>4.89</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>At risk subjects</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Noninferiority was concluded if the lower limit of the 2-sided 97.6% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.</non_inferiority_desc>
            <param_type>GMT ratio (B strain)</param_type>
            <param_value>1.17</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.37</ci_lower_limit>
            <ci_upper_limit>3.67</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparison of Antibody Responses of aTIV Versus Comparator TIV and TIV in Terms of Percentage of Subjects Achieving Seroconversion or ≥4-fold Increase in HI Titer Against Homologous Strains in Subjects at Risk/Not at Risk, by Age Subgroup</title>
        <description>The non-inferiority of HI antibody responses of aTIV to that of the licensed comparator TIV and to investigational TIV was assessed in terms of percentage of subjects achieving seroconversion or ≥4-fold increase in HI titers at three weeks after last vaccination against the three homologous vaccine strains in subjects with a defined set of underlying medical conditions (at risk) and in healthy subjects (not at risk) , by age sub group.</description>
        <time_frame>Day 50</time_frame>
        <population>Analysis was done on the Per Protocol Set.</population>
        <group_list>
          <group group_id="O1">
            <title>aTIV (6 to &lt;72 Months)</title>
            <description>Subjects received an investigational MF59-adjuvanted trivalent influenza vaccine (aTIV), subjects aged between 6 to &lt;36 months received two doses (Day 1 &amp; 29) while subjects aged ≥36 months received one dose (at Day 1) of the vaccine</description>
          </group>
          <group group_id="O2">
            <title>Compartor TIV (6 to &lt;72 Months)</title>
            <description>Subjects received a licensed comparator trivalent split influenza vaccine (comparator TIV), subjects aged between 6 to &lt;36 months received two doses (Day 1 &amp; 29) while subjects aged ≥36 months received one dose (at Day 1) of the vaccine</description>
          </group>
          <group group_id="O3">
            <title>TIV (6 to &lt;72 Months)</title>
            <description>Subjects received an investigational trivalent split influenza vaccine (TIV), subjects aged between 6 to &lt;36 months received two doses (Day 1 &amp; 29) while subjects aged ≥36 months received one dose (Day 1) of the vaccine</description>
          </group>
          <group group_id="O4">
            <title>aTIV (6 to &lt;36 Months)</title>
            <description>Subjects received two doses (Day 1 &amp; 29) of an investigational MF59-adjuvanted trivalent influenza vaccine (aTIV)</description>
          </group>
          <group group_id="O5">
            <title>Compartor TIV (6 to &lt;36 Months)</title>
            <description>Subjects received two doses (Day 1 &amp; 29) of a licensed comparator trivalent split influenza vaccine (comparator TIV)</description>
          </group>
          <group group_id="O6">
            <title>TIV (6 to &lt;36 Months)</title>
            <description>Subjects received two doses (Day 1 &amp; 29) of an investigational trivalent split influenza vaccine (TIV)</description>
          </group>
          <group group_id="O7">
            <title>aTIV (36 to &lt;72 Months)</title>
            <description>Subjects received one dose (Day 1) of investigational MF59-adjuvanted trivalent influenza vaccine (aTIV)</description>
          </group>
          <group group_id="O8">
            <title>Comparator TIV (36 to &lt;72 Months)</title>
            <description>Subjects received one dose (Day 1) of a licensed comparator trivalent split influenza vaccine (comparator TIV)</description>
          </group>
          <group group_id="O9">
            <title>TIV (36 to &lt;72 Months)</title>
            <description>Subjects received one dose (Day 1) of an investigational trivalent split influenza vaccine (TIV)</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of Antibody Responses of aTIV Versus Comparator TIV and TIV in Terms of Percentage of Subjects Achieving Seroconversion or ≥4-fold Increase in HI Titer Against Homologous Strains in Subjects at Risk/Not at Risk, by Age Subgroup</title>
          <description>The non-inferiority of HI antibody responses of aTIV to that of the licensed comparator TIV and to investigational TIV was assessed in terms of percentage of subjects achieving seroconversion or ≥4-fold increase in HI titers at three weeks after last vaccination against the three homologous vaccine strains in subjects with a defined set of underlying medical conditions (at risk) and in healthy subjects (not at risk) , by age sub group.</description>
          <population>Analysis was done on the Per Protocol Set.</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="660"/>
                <count group_id="O2" value="722"/>
                <count group_id="O3" value="739"/>
                <count group_id="O4" value="425"/>
                <count group_id="O5" value="612"/>
                <count group_id="O6" value="623"/>
                <count group_id="O7" value="235"/>
                <count group_id="O8" value="110"/>
                <count group_id="O9" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1 norisk(N=658,722,739,425,612,623,233,110,116)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93" lower_limit="91" upper_limit="95"/>
                    <measurement group_id="O2" value="85" lower_limit="82" upper_limit="87"/>
                    <measurement group_id="O3" value="79" lower_limit="76" upper_limit="82"/>
                    <measurement group_id="O4" value="95" lower_limit="92" upper_limit="97"/>
                    <measurement group_id="O5" value="84" lower_limit="81" upper_limit="87"/>
                    <measurement group_id="O6" value="78" lower_limit="75" upper_limit="82"/>
                    <measurement group_id="O7" value="91" lower_limit="86" upper_limit="94"/>
                    <measurement group_id="O8" value="88" lower_limit="81" upper_limit="94"/>
                    <measurement group_id="O9" value="83" lower_limit="75" upper_limit="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2 norisk(N=660,722,739,425,612,623,235,110,116)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97" lower_limit="95" upper_limit="98"/>
                    <measurement group_id="O2" value="93" lower_limit="91" upper_limit="94"/>
                    <measurement group_id="O3" value="90" lower_limit="87" upper_limit="92"/>
                    <measurement group_id="O4" value="98" lower_limit="96" upper_limit="99"/>
                    <measurement group_id="O5" value="93" lower_limit="91" upper_limit="95"/>
                    <measurement group_id="O6" value="90" lower_limit="88" upper_limit="93"/>
                    <measurement group_id="O7" value="94" lower_limit="91" upper_limit="97"/>
                    <measurement group_id="O8" value="90" lower_limit="83" upper_limit="95"/>
                    <measurement group_id="O9" value="86" lower_limit="79" upper_limit="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B norisk(N=660,722,739,425,612,623,235,110,116)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98" lower_limit="96" upper_limit="99"/>
                    <measurement group_id="O2" value="86" lower_limit="83" upper_limit="88"/>
                    <measurement group_id="O3" value="84" lower_limit="82" upper_limit="87"/>
                    <measurement group_id="O4" value="98" lower_limit="96" upper_limit="99"/>
                    <measurement group_id="O5" value="85" lower_limit="82" upper_limit="88"/>
                    <measurement group_id="O6" value="83" lower_limit="79" upper_limit="86"/>
                    <measurement group_id="O7" value="98" lower_limit="95" upper_limit="99"/>
                    <measurement group_id="O8" value="90" lower_limit="83" upper_limit="95"/>
                    <measurement group_id="O9" value="94" lower_limit="88" upper_limit="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H1N1 at risk (N=22,35,26,12,23,19,10,12,7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82" lower_limit="60" upper_limit="95"/>
                    <measurement group_id="O2" value="83" lower_limit="66" upper_limit="93"/>
                    <measurement group_id="O3" value="85" lower_limit="65" upper_limit="96"/>
                    <measurement group_id="O4" value="92" lower_limit="62" upper_limit="100"/>
                    <measurement group_id="O5" value="87" lower_limit="66" upper_limit="97"/>
                    <measurement group_id="O6" value="89" lower_limit="67" upper_limit="99"/>
                    <measurement group_id="O7" value="70" lower_limit="35" upper_limit="93"/>
                    <measurement group_id="O8" value="75" lower_limit="43" upper_limit="95"/>
                    <measurement group_id="O9" value="71" lower_limit="29" upper_limit="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2 at risk(N=22,35,26,12,23,19,10,12,7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86" lower_limit="65" upper_limit="97"/>
                    <measurement group_id="O2" value="86" lower_limit="70" upper_limit="95"/>
                    <measurement group_id="O3" value="81" lower_limit="61" upper_limit="93"/>
                    <measurement group_id="O4" value="83" lower_limit="52" upper_limit="98"/>
                    <measurement group_id="O5" value="78" lower_limit="56" upper_limit="93"/>
                    <measurement group_id="O6" value="74" lower_limit="49" upper_limit="91"/>
                    <measurement group_id="O7" value="90" lower_limit="55" upper_limit="100"/>
                    <measurement group_id="O8" value="100" lower_limit="74" upper_limit="100"/>
                    <measurement group_id="O9" value="100" lower_limit="59" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B at risk(N=22,35,26,12,23,19,10,12,7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="85" upper_limit="100"/>
                    <measurement group_id="O2" value="86" lower_limit="70" upper_limit="98"/>
                    <measurement group_id="O3" value="88" lower_limit="70" upper_limit="98"/>
                    <measurement group_id="O4" value="100" lower_limit="74" upper_limit="100"/>
                    <measurement group_id="O5" value="91" lower_limit="72" upper_limit="99"/>
                    <measurement group_id="O6" value="84" lower_limit="60" upper_limit="97"/>
                    <measurement group_id="O7" value="100" lower_limit="69" upper_limit="100"/>
                    <measurement group_id="O8" value="75" lower_limit="43" upper_limit="95"/>
                    <measurement group_id="O9" value="100" lower_limit="59" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>No risk subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was &gt; -10%</non_inferiority_desc>
            <param_type>Group difference (H1N1 strain)</param_type>
            <param_value>9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.4</ci_lower_limit>
            <ci_upper_limit>12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>No risk subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was &gt; -10%.</non_inferiority_desc>
            <param_type>Group difference (H3N2 strain)</param_type>
            <param_value>4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.8</ci_lower_limit>
            <ci_upper_limit>6.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>No risk subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was &gt; -10%.</non_inferiority_desc>
            <param_type>Group difference (B strain)</param_type>
            <param_value>12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>9.2</ci_lower_limit>
            <ci_upper_limit>14.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>At risk subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was &gt; -10%.</non_inferiority_desc>
            <param_type>Group difference (H1N1 strain)</param_type>
            <param_value>-1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-24</ci_lower_limit>
            <ci_upper_limit>18.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>At risk subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was &gt; -10%.</non_inferiority_desc>
            <param_type>Group difference (H3N2 strain)</param_type>
            <param_value>1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-21.2</ci_lower_limit>
            <ci_upper_limit>18.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>At risk subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was &gt; -10%.</non_inferiority_desc>
            <param_type>Group difference (B strain)</param_type>
            <param_value>14</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.6</ci_lower_limit>
            <ci_upper_limit>29.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>No risk subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was &gt; -10%.</non_inferiority_desc>
            <param_type>Group difference (H1N1 strain)</param_type>
            <param_value>14</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>10.7</ci_lower_limit>
            <ci_upper_limit>17.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>No risk subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was &gt; -10%.</non_inferiority_desc>
            <param_type>Group difference (H3N2 strain)</param_type>
            <param_value>7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.6</ci_lower_limit>
            <ci_upper_limit>9.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>No risk subjects</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was &gt; -10%.</non_inferiority_desc>
            <param_type>Group difference (B strain)</param_type>
            <param_value>13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>10.7</ci_lower_limit>
            <ci_upper_limit>16.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>At risk subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was &gt; -10%.</non_inferiority_desc>
            <param_type>Group difference (H1N1 strain)</param_type>
            <param_value>-3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-26.1</ci_lower_limit>
            <ci_upper_limit>19.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>At risk subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was &gt; -10%.</non_inferiority_desc>
            <param_type>Group difference (H3N2 strain)</param_type>
            <param_value>6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-17.5</ci_lower_limit>
            <ci_upper_limit>27.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>At risk subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was &gt; -10%.</non_inferiority_desc>
            <param_type>Group difference (B strain)</param_type>
            <param_value>12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.4</ci_lower_limit>
            <ci_upper_limit>29.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>No risk subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was &gt; -10%.</non_inferiority_desc>
            <param_type>Group difference (H1N1 strain)</param_type>
            <param_value>11</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>7.2</ci_lower_limit>
            <ci_upper_limit>14.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>No risk subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was &gt; -10%.</non_inferiority_desc>
            <param_type>Group difference (H3N2 strain)</param_type>
            <param_value>5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.6</ci_lower_limit>
            <ci_upper_limit>7.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>No risk subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was &gt; -10%.</non_inferiority_desc>
            <param_type>Group difference (B strain)</param_type>
            <param_value>13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>9.5</ci_lower_limit>
            <ci_upper_limit>15.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>At risk subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was &gt; -10%.</non_inferiority_desc>
            <param_type>Group difference (H1N1 strain)</param_type>
            <param_value>5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-24.7</ci_lower_limit>
            <ci_upper_limit>26.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>At risk subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was &gt; -10%.</non_inferiority_desc>
            <param_type>Group difference (H3N2 strain)</param_type>
            <param_value>5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-26.9</ci_lower_limit>
            <ci_upper_limit>30.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>At risk subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was &gt; -10%.</non_inferiority_desc>
            <param_type>Group difference (B strain)</param_type>
            <param_value>9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-16.9</ci_lower_limit>
            <ci_upper_limit>27.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>No risk subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was &gt; -10%.</non_inferiority_desc>
            <param_type>Group difference (H1N1 strain)</param_type>
            <param_value>16</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>12.4</ci_lower_limit>
            <ci_upper_limit>20.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>No risk subjects</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was &gt; -10%.</non_inferiority_desc>
            <param_type>Group difference (H3N2 strain)</param_type>
            <param_value>8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.1</ci_lower_limit>
            <ci_upper_limit>10.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>No risk subjects</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was &gt; -10%.</non_inferiority_desc>
            <param_type>Group difference (B strain)</param_type>
            <param_value>15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>12</ci_lower_limit>
            <ci_upper_limit>18.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>At risk subjects</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was &gt; -10%.</non_inferiority_desc>
            <param_type>Group difference (H1N1 strain)</param_type>
            <param_value>2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-27.1</ci_lower_limit>
            <ci_upper_limit>25.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>At risk subjects</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was &gt; -10%.</non_inferiority_desc>
            <param_type>Group difference (H3N2 strain)</param_type>
            <param_value>10</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-23.5</ci_lower_limit>
            <ci_upper_limit>37.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>At risk subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was &gt; -10%.</non_inferiority_desc>
            <param_type>Group difference (B strain)</param_type>
            <param_value>16</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.7</ci_lower_limit>
            <ci_upper_limit>38</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>No risk subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was &gt; -10%.</non_inferiority_desc>
            <param_type>Group difference (H1N1 strain)</param_type>
            <param_value>2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.2</ci_lower_limit>
            <ci_upper_limit>10.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>No risk subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was &gt; -10%.</non_inferiority_desc>
            <param_type>Group difference (H3N2 subjects)</param_type>
            <param_value>4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.2</ci_lower_limit>
            <ci_upper_limit>11.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>No risk subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was &gt; -10%.</non_inferiority_desc>
            <param_type>Group difference (B strain)</param_type>
            <param_value>8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.9</ci_lower_limit>
            <ci_upper_limit>15.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>At risk subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was &gt; -10%.</non_inferiority_desc>
            <param_type>Group difference (H1N1 strain)</param_type>
            <param_value>-5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-42.4</ci_lower_limit>
            <ci_upper_limit>32</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>At risk subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was &gt; -10%.</non_inferiority_desc>
            <param_type>Group difference (H3N2 strain)</param_type>
            <param_value>-10</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-41.2</ci_lower_limit>
            <ci_upper_limit>16.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>At risk subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was &gt; -10%.</non_inferiority_desc>
            <param_type>Group difference (B strain)</param_type>
            <param_value>25</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.1</ci_lower_limit>
            <ci_upper_limit>53.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>No risk subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was &gt; -10%.</non_inferiority_desc>
            <param_type>Group difference (H1N1 strain)</param_type>
            <param_value>8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1</ci_lower_limit>
            <ci_upper_limit>16.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>No risk subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was &gt; -10%.</non_inferiority_desc>
            <param_type>Group difference (H3N2 strain)</param_type>
            <param_value>8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2</ci_lower_limit>
            <ci_upper_limit>16.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>No risk subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was &gt; -10%.</non_inferiority_desc>
            <param_type>Group difference (B strain)</param_type>
            <param_value>4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0</ci_lower_limit>
            <ci_upper_limit>10</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>At risk subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was &gt; -10%.</non_inferiority_desc>
            <param_type>Group difference (H1N1 strain)</param_type>
            <param_value>-1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-42.1</ci_lower_limit>
            <ci_upper_limit>43</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>At risk subjects</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was &gt; -10%.</non_inferiority_desc>
            <param_type>Group difference (H3N2 strain)</param_type>
            <param_value>-10</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-41.5</ci_lower_limit>
            <ci_upper_limit>28.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>At risk subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was &gt; -10%.</non_inferiority_desc>
            <param_type>Group difference (B strain)</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-29</ci_lower_limit>
            <ci_upper_limit>36.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparison of Antibody Responses of TIV Versus Comparator TIV in Terms of Percentage of Subjects Achieving Seroconversion or ≥4-fold Increase in HI Titer Against Homologous Strains in Subjects at Risk/Not at Risk, by Age Sub Group-FAS</title>
        <description>The superiority of HI antibody responses of aTIV compared to TIV and comparator TIV assessed in terms of of percentage of subjects achieving seroconversion or ≥4-fold increase in HI Titer at three weeks after last vaccination against the three homologous vaccine strains in subjects with a defined set of underlying medical conditions (at risk) and healthy subjects (not at risk), by age sub group.</description>
        <time_frame>Day 50</time_frame>
        <population>Analysis was done on the Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>aTIV (6 to &lt;72 Months)</title>
            <description>Subjects received an investigational MF59-adjuvanted trivalent influenza vaccine (aTIV), subjects aged between 6 to &lt;36 months received two doses (Day 1 &amp; 29) while subjects aged ≥36 months received one dose (at Day 1) of the vaccine</description>
          </group>
          <group group_id="O2">
            <title>Compartor TIV (6 to &lt;72 Months)</title>
            <description>Subjects received a licensed comparator trivalent split influenza vaccine (comparator TIV), subjects aged between 6 to &lt;36 months received two doses (Day 1 &amp; 29) while subjects aged ≥36 months received one dose (at Day 1) of the vaccine</description>
          </group>
          <group group_id="O3">
            <title>TIV (6 to &lt;72 Months)</title>
            <description>Subjects received an investigational trivalent split influenza vaccine (TIV), subjects aged between 6 to &lt;36 months received two doses (Day 1 &amp; 29) while subjects aged ≥36 months received one dose (Day 1) of the vaccine</description>
          </group>
          <group group_id="O4">
            <title>aTIV (6 to &lt;36 Months)</title>
            <description>Subjects received two doses (Day 1 &amp; 29) of an investigational MF59-adjuvanted trivalent influenza vaccine (aTIV)</description>
          </group>
          <group group_id="O5">
            <title>Compartor TIV (6 to &lt;36 Months)</title>
            <description>Subjects received two doses (Day 1 &amp; 29) of a licensed comparator trivalent split influenza vaccine (comparator TIV)</description>
          </group>
          <group group_id="O6">
            <title>TIV (6 to &lt;36 Months)</title>
            <description>Subjects received two doses (Day 1 &amp; 29) of an investigational trivalent split influenza vaccine (TIV)</description>
          </group>
          <group group_id="O7">
            <title>aTIV (36 to &lt;72 Months)</title>
            <description>Subjects received one dose (Day 1) of investigational MF59-adjuvanted trivalent influenza vaccine (aTIV)</description>
          </group>
          <group group_id="O8">
            <title>Comparator TIV (36 to &lt;72 Months)</title>
            <description>Subjects received one dose (Day 1) of a licensed comparator trivalent split influenza vaccine (comparator TIV)</description>
          </group>
          <group group_id="O9">
            <title>TIV (36 to &lt;72 Months)</title>
            <description>Subjects received one dose (Day 1) of an investigational trivalent split influenza vaccine (TIV)</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of Antibody Responses of TIV Versus Comparator TIV in Terms of Percentage of Subjects Achieving Seroconversion or ≥4-fold Increase in HI Titer Against Homologous Strains in Subjects at Risk/Not at Risk, by Age Sub Group-FAS</title>
          <description>The superiority of HI antibody responses of aTIV compared to TIV and comparator TIV assessed in terms of of percentage of subjects achieving seroconversion or ≥4-fold increase in HI Titer at three weeks after last vaccination against the three homologous vaccine strains in subjects with a defined set of underlying medical conditions (at risk) and healthy subjects (not at risk), by age sub group.</description>
          <population>Analysis was done on the Full Analysis Set.</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="719"/>
                <count group_id="O2" value="799"/>
                <count group_id="O3" value="814"/>
                <count group_id="O4" value="459"/>
                <count group_id="O5" value="673"/>
                <count group_id="O6" value="688"/>
                <count group_id="O7" value="260"/>
                <count group_id="O8" value="126"/>
                <count group_id="O9" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1 norisk(N=717,799,814,459,673,688,258,126,126)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93" lower_limit="91" upper_limit="95"/>
                    <measurement group_id="O2" value="84" lower_limit="81" upper_limit="86"/>
                    <measurement group_id="O3" value="79" lower_limit="76" upper_limit="81"/>
                    <measurement group_id="O4" value="95" lower_limit="92" upper_limit="96"/>
                    <measurement group_id="O5" value="83" lower_limit="80" upper_limit="86"/>
                    <measurement group_id="O6" value="78" lower_limit="75" upper_limit="81"/>
                    <measurement group_id="O7" value="91" lower_limit="87" upper_limit="94"/>
                    <measurement group_id="O8" value="89" lower_limit="82" upper_limit="94"/>
                    <measurement group_id="O9" value="81" lower_limit="73" upper_limit="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2 norisk(N=719,799,814,459,673,688,260,126,126)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97" lower_limit="95" upper_limit="98"/>
                    <measurement group_id="O2" value="93" lower_limit="91" upper_limit="94"/>
                    <measurement group_id="O3" value="90" lower_limit="88" upper_limit="92"/>
                    <measurement group_id="O4" value="98" lower_limit="96" upper_limit="99"/>
                    <measurement group_id="O5" value="93" lower_limit="91" upper_limit="95"/>
                    <measurement group_id="O6" value="91" lower_limit="88" upper_limit="93"/>
                    <measurement group_id="O7" value="95" lower_limit="91" upper_limit="97"/>
                    <measurement group_id="O8" value="91" lower_limit="85" upper_limit="96"/>
                    <measurement group_id="O9" value="87" lower_limit="79" upper_limit="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B norisk(N=719,799,814,459,673,688,260,126,126)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97" lower_limit="96" upper_limit="99"/>
                    <measurement group_id="O2" value="86" lower_limit="84" upper_limit="89"/>
                    <measurement group_id="O3" value="84" lower_limit="82" upper_limit="87"/>
                    <measurement group_id="O4" value="98" lower_limit="96" upper_limit="99"/>
                    <measurement group_id="O5" value="85" lower_limit="83" upper_limit="88"/>
                    <measurement group_id="O6" value="83" lower_limit="80" upper_limit="85"/>
                    <measurement group_id="O7" value="97" lower_limit="95" upper_limit="99"/>
                    <measurement group_id="O8" value="91" lower_limit="85" upper_limit="96"/>
                    <measurement group_id="O9" value="94" lower_limit="88" upper_limit="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H1N1 at risk(N=28,40,35,17,26,26,11,14,9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79" lower_limit="59" upper_limit="92"/>
                    <measurement group_id="O2" value="83" lower_limit="67" upper_limit="93"/>
                    <measurement group_id="O3" value="83" lower_limit="66" upper_limit="93"/>
                    <measurement group_id="O4" value="82" lower_limit="57" upper_limit="96"/>
                    <measurement group_id="O5" value="85" lower_limit="65" upper_limit="96"/>
                    <measurement group_id="O6" value="85" lower_limit="65" upper_limit="96"/>
                    <measurement group_id="O7" value="73" lower_limit="39" upper_limit="94"/>
                    <measurement group_id="O8" value="79" lower_limit="49" upper_limit="95"/>
                    <measurement group_id="O9" value="78" lower_limit="40" upper_limit="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2 at risk(N=28,40,35,17,26,26,11,14,9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89" lower_limit="72" upper_limit="98"/>
                    <measurement group_id="O2" value="85" lower_limit="70" upper_limit="94"/>
                    <measurement group_id="O3" value="83" lower_limit="66" upper_limit="93"/>
                    <measurement group_id="O4" value="88" lower_limit="64" upper_limit="99"/>
                    <measurement group_id="O5" value="77" lower_limit="56" upper_limit="91"/>
                    <measurement group_id="O6" value="77" lower_limit="56" upper_limit="91"/>
                    <measurement group_id="O7" value="91" lower_limit="59" upper_limit="100"/>
                    <measurement group_id="O8" value="100" lower_limit="77" upper_limit="100"/>
                    <measurement group_id="O9" value="100" lower_limit="66" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B at risk(N=28,40,35,17,26,26,11,14,9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96" lower_limit="82" upper_limit="100"/>
                    <measurement group_id="O2" value="88" lower_limit="73" upper_limit="96"/>
                    <measurement group_id="O3" value="89" lower_limit="73" upper_limit="97"/>
                    <measurement group_id="O4" value="94" lower_limit="71" upper_limit="100"/>
                    <measurement group_id="O5" value="92" lower_limit="75" upper_limit="99"/>
                    <measurement group_id="O6" value="85" lower_limit="65" upper_limit="96"/>
                    <measurement group_id="O7" value="100" lower_limit="72" upper_limit="100"/>
                    <measurement group_id="O8" value="79" lower_limit="49" upper_limit="95"/>
                    <measurement group_id="O9" value="100" lower_limit="66" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>No risk subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was &gt; -10%.</non_inferiority_desc>
            <param_type>Group difference (H1N1 strain)</param_type>
            <param_value>10</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>6.4</ci_lower_limit>
            <ci_upper_limit>12.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>No risk subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was &gt; -10%.</non_inferiority_desc>
            <param_type>Group difference (H3N2 strain)</param_type>
            <param_value>4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.8</ci_lower_limit>
            <ci_upper_limit>6.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>No risk subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was &gt; -10%.</non_inferiority_desc>
            <param_type>Group difference (B strain)</param_type>
            <param_value>11</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>8.6</ci_lower_limit>
            <ci_upper_limit>13.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>At risk subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was &gt; -10%.</non_inferiority_desc>
            <param_type>Group difference (H1N1 strain)</param_type>
            <param_value>-4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-24.7</ci_lower_limit>
            <ci_upper_limit>14.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>At risk subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was &gt; -10%.</non_inferiority_desc>
            <param_type>Group difference (H3N2 strain)</param_type>
            <param_value>4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-14.4</ci_lower_limit>
            <ci_upper_limit>20.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>At risk subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was &gt; -10%.</non_inferiority_desc>
            <param_type>Group difference (B strain)</param_type>
            <param_value>9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.8</ci_lower_limit>
            <ci_upper_limit>23.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>No risk subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was &gt; -10%.</non_inferiority_desc>
            <param_type>Group difference (H1N1 strain)</param_type>
            <param_value>15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>11.3</ci_lower_limit>
            <ci_upper_limit>18.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>No risk subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was &gt; -10%.</non_inferiority_desc>
            <param_type>Group difference (H3N2 strain)</param_type>
            <param_value>7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.2</ci_lower_limit>
            <ci_upper_limit>9.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>No risk subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was &gt; -10%.</non_inferiority_desc>
            <param_type>Group difference (B strain)</param_type>
            <param_value>13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>10.5</ci_lower_limit>
            <ci_upper_limit>16.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>At risk subjects</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was &gt; -10%.</non_inferiority_desc>
            <param_type>Group difference (H1N1 strain)</param_type>
            <param_value>-4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-25.3</ci_lower_limit>
            <ci_upper_limit>15.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>At risk subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was &gt; -10%.</non_inferiority_desc>
            <param_type>Group difference (H3N2 strain)</param_type>
            <param_value>6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.7</ci_lower_limit>
            <ci_upper_limit>24.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>At risk subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was &gt; -10%.</non_inferiority_desc>
            <param_type>Group differences (B strain)</param_type>
            <param_value>8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.8</ci_lower_limit>
            <ci_upper_limit>23.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>No risk subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was &gt; -10%.</non_inferiority_desc>
            <param_type>Group difference (H1N1 strain)</param_type>
            <param_value>12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>8.2</ci_lower_limit>
            <ci_upper_limit>15.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>No risk subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was &gt; -10%.</non_inferiority_desc>
            <param_type>Group difference (H3N2 strain)</param_type>
            <param_value>5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.5</ci_lower_limit>
            <ci_upper_limit>7.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>No risk subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was &gt; -10%.</non_inferiority_desc>
            <param_type>Group difference (B strain)</param_type>
            <param_value>12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>9.2</ci_lower_limit>
            <ci_upper_limit>15.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>At risk subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was &gt; -10%.</non_inferiority_desc>
            <param_type>Group difference (H1N1 strain)</param_type>
            <param_value>-2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-28.5</ci_lower_limit>
            <ci_upper_limit>20.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>At risk subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was &gt; -10%.</non_inferiority_desc>
            <param_type>Group difference (H3N2 strain)</param_type>
            <param_value>11</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-14.9</ci_lower_limit>
            <ci_upper_limit>33.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>At risk subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was &gt; -10%.</non_inferiority_desc>
            <param_type>Group difference (B strain)</param_type>
            <param_value>2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-20.7</ci_lower_limit>
            <ci_upper_limit>19.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>No risk subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was &gt; -10%.</non_inferiority_desc>
            <param_type>Group difference (H1N1 strain)</param_type>
            <param_value>16</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>12.6</ci_lower_limit>
            <ci_upper_limit>20.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>No risk subjects</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was &gt; -10%.</non_inferiority_desc>
            <param_type>Group difference (H3N2 strain)</param_type>
            <param_value>7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.6</ci_lower_limit>
            <ci_upper_limit>9.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>No risk subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was &gt; -10%.</non_inferiority_desc>
            <param_type>Group difference (B strain)</param_type>
            <param_value>15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>11.9</ci_lower_limit>
            <ci_upper_limit>18.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>At risk subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was &gt; -10%.</non_inferiority_desc>
            <param_type>Group difference (H1N1 strain)</param_type>
            <param_value>-2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-28.5</ci_lower_limit>
            <ci_upper_limit>20.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>At risk subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was &gt; -10%.</non_inferiority_desc>
            <param_type>Group difference (H3N2 strain)</param_type>
            <param_value>11</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-14.9</ci_lower_limit>
            <ci_upper_limit>33.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>At risk subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was &gt; -10%.</non_inferiority_desc>
            <param_type>Group difference (B strain)</param_type>
            <param_value>10</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-14</ci_lower_limit>
            <ci_upper_limit>29.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>No risk subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was &gt; -10%.</non_inferiority_desc>
            <param_type>Group difference (H1N1 strain)</param_type>
            <param_value>2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.8</ci_lower_limit>
            <ci_upper_limit>9.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>No risk subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was &gt; -10%.</non_inferiority_desc>
            <param_type>Group difference (H3N2 strain)</param_type>
            <param_value>3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.8</ci_lower_limit>
            <ci_upper_limit>10</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>No risk subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was &gt; -10%.</non_inferiority_desc>
            <param_type>Group difference (B strain)</param_type>
            <param_value>6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.5</ci_lower_limit>
            <ci_upper_limit>12.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>At risk subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was &gt; -10%.</non_inferiority_desc>
            <param_type>Group difference (H1N1 strain)</param_type>
            <param_value>-6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-40.7</ci_lower_limit>
            <ci_upper_limit>27.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>At risk subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was &gt; -10%.</non_inferiority_desc>
            <param_type>Group difference (H3N2 strain)</param_type>
            <param_value>-9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-38.4</ci_lower_limit>
            <ci_upper_limit>14.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>At risk subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was &gt; -10%.</non_inferiority_desc>
            <param_type>Group difference (B strain)</param_type>
            <param_value>21</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.9</ci_lower_limit>
            <ci_upper_limit>48.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>No risk subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was &gt; -10%.</non_inferiority_desc>
            <param_type>Group difference (H1N1 strain)</param_type>
            <param_value>10</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3</ci_lower_limit>
            <ci_upper_limit>18.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>No risk subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was &gt; -10%.</non_inferiority_desc>
            <param_type>Group difference (H3N2 strain)</param_type>
            <param_value>8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.2</ci_lower_limit>
            <ci_upper_limit>15.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>No risk subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was &gt; -10%.</non_inferiority_desc>
            <param_type>Group difference (B strain)</param_type>
            <param_value>4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0</ci_lower_limit>
            <ci_upper_limit>9.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>At risk subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was &gt; -10%.</non_inferiority_desc>
            <param_type>Group difference (H1N1 strain)</param_type>
            <param_value>-5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-41.7</ci_lower_limit>
            <ci_upper_limit>35</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>At risk subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was &gt; -10%.</non_inferiority_desc>
            <param_type>Group difference (H3N2 strain)</param_type>
            <param_value>-9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-38.6</ci_lower_limit>
            <ci_upper_limit>23.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>At risk subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was &gt; -10%.</non_inferiority_desc>
            <param_type>Group difference (B strain)</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-26.9</ci_lower_limit>
            <ci_upper_limit>31</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparison of Antibody Responses of aTIV With TIV and Comparator TIV in Terms of GMTs Against Homologous Strains, at Risk/Not at Risk, by Age Sub Group-FAS</title>
        <description>The superiority of HI antibody responses of aTIV compared to TIV and comparator TIV assessed in terms of post vaccination GMTs at three weeks after last vaccination against the three homologous vaccine strains, in subjects with a defined set of underlying medical conditions (at risk) and in healthy subjects (not at risk), by age sub group.</description>
        <time_frame>Day 50</time_frame>
        <population>Analysis was done on Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>aTIV (6 to &lt;72 Months)</title>
            <description>Subjects received an investigational MF59-adjuvanted trivalent influenza vaccine (aTIV), subjects aged between 6 to &lt;36 months received two doses (Day 1 &amp; 29) while subjects aged ≥36 months received one dose (at Day 1) of the vaccine</description>
          </group>
          <group group_id="O2">
            <title>Compartor TIV (6 to &lt;72 Months)</title>
            <description>Subjects received a licensed comparator trivalent split influenza vaccine (comparator TIV), subjects aged between 6 to &lt;36 months received two doses (Day 1 &amp; 29) while subjects aged ≥36 months received one dose (at Day 1) of the vaccine</description>
          </group>
          <group group_id="O3">
            <title>TIV (6 to &lt;72 Months)</title>
            <description>Subjects received an investigational trivalent split influenza vaccine (TIV), subjects aged between 6 to &lt;36 months received two doses (Day 1 &amp; 29) while subjects aged ≥36 months received one dose (Day 1) of the vaccine</description>
          </group>
          <group group_id="O4">
            <title>aTIV (6 to &lt;36 Months)</title>
            <description>Subjects received two doses (Day 1 &amp; 29) of an investigational MF59-adjuvanted trivalent influenza vaccine (aTIV)</description>
          </group>
          <group group_id="O5">
            <title>Compartor TIV (6 to &lt;36 Months)</title>
            <description>Subjects received two doses (Day 1 &amp; 29) of a licensed comparator trivalent split influenza vaccine (comparator TIV)</description>
          </group>
          <group group_id="O6">
            <title>TIV (6 to &lt;36 Months)</title>
            <description>Subjects received two doses (Day 1 &amp; 29) of an investigational trivalent split influenza vaccine (TIV)</description>
          </group>
          <group group_id="O7">
            <title>aTIV (36 to &lt;72 Months)</title>
            <description>Subjects received one dose (Day 1) of investigational MF59-adjuvanted trivalent influenza vaccine (aTIV)</description>
          </group>
          <group group_id="O8">
            <title>Comparator TIV (36 to &lt;72 Months)</title>
            <description>Subjects received one dose (Day 1) of a licensed comparator trivalent split influenza vaccine (comparator TIV)</description>
          </group>
          <group group_id="O9">
            <title>TIV (36 to &lt;72 Months)</title>
            <description>Subjects received one dose (Day 1) of an investigational trivalent split influenza vaccine (TIV)</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of Antibody Responses of aTIV With TIV and Comparator TIV in Terms of GMTs Against Homologous Strains, at Risk/Not at Risk, by Age Sub Group-FAS</title>
          <description>The superiority of HI antibody responses of aTIV compared to TIV and comparator TIV assessed in terms of post vaccination GMTs at three weeks after last vaccination against the three homologous vaccine strains, in subjects with a defined set of underlying medical conditions (at risk) and in healthy subjects (not at risk), by age sub group.</description>
          <population>Analysis was done on Full Analysis Set.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="719"/>
                <count group_id="O2" value="799"/>
                <count group_id="O3" value="814"/>
                <count group_id="O4" value="459"/>
                <count group_id="O5" value="673"/>
                <count group_id="O6" value="688"/>
                <count group_id="O7" value="260"/>
                <count group_id="O8" value="126"/>
                <count group_id="O9" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1 norisk(N=718,799,814,459,673,688,259,126,126)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1509" lower_limit="1357" upper_limit="1677"/>
                    <measurement group_id="O2" value="569" lower_limit="515" upper_limit="629"/>
                    <measurement group_id="O3" value="422" lower_limit="382" upper_limit="466"/>
                    <measurement group_id="O4" value="1336" lower_limit="1166" upper_limit="1530"/>
                    <measurement group_id="O5" value="474" lower_limit="424" upper_limit="530"/>
                    <measurement group_id="O6" value="365" lower_limit="326" upper_limit="407"/>
                    <measurement group_id="O7" value="2077" lower_limit="1815" upper_limit="2376"/>
                    <measurement group_id="O8" value="1413" lower_limit="1165" upper_limit="1713"/>
                    <measurement group_id="O9" value="813" lower_limit="670" upper_limit="986"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2 norisk(N=719,799,814,459,673,688,260,126,126)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1894" lower_limit="1775" upper_limit="2022"/>
                    <measurement group_id="O2" value="1015" lower_limit="954" upper_limit="1080"/>
                    <measurement group_id="O3" value="794" lower_limit="747" upper_limit="844"/>
                    <measurement group_id="O4" value="1851" lower_limit="1705" upper_limit="2010"/>
                    <measurement group_id="O5" value="905" lower_limit="845" upper_limit="968"/>
                    <measurement group_id="O6" value="686" lower_limit="641" upper_limit="733"/>
                    <measurement group_id="O7" value="2343" lower_limit="2120" upper_limit="2589"/>
                    <measurement group_id="O8" value="1582" lower_limit="1370" upper_limit="1826"/>
                    <measurement group_id="O9" value="1475" lower_limit="1278" upper_limit="1703"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B norisk(N=719,799,814,459,673,688,260,126,126)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="484" lower_limit="444" upper_limit="527"/>
                    <measurement group_id="O2" value="164" lower_limit="151" upper_limit="178"/>
                    <measurement group_id="O3" value="155" lower_limit="143" upper_limit="168"/>
                    <measurement group_id="O4" value="545" lower_limit="487" upper_limit="608"/>
                    <measurement group_id="O5" value="150" lower_limit="137" upper_limit="164"/>
                    <measurement group_id="O6" value="139" lower_limit="127" upper_limit="152"/>
                    <measurement group_id="O7" value="432" lower_limit="383" upper_limit="487"/>
                    <measurement group_id="O8" value="243" lower_limit="205" upper_limit="289"/>
                    <measurement group_id="O9" value="253" lower_limit="212" upper_limit="300"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H1N1 at risk(N=28,40,35,17,26,26,11,14,9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1541" lower_limit="948" upper_limit="2504"/>
                    <measurement group_id="O2" value="830" lower_limit="553" upper_limit="1244"/>
                    <measurement group_id="O3" value="586" lower_limit="380" upper_limit="905"/>
                    <measurement group_id="O4" value="1277" lower_limit="674" upper_limit="2418"/>
                    <measurement group_id="O5" value="617" lower_limit="370" upper_limit="1028"/>
                    <measurement group_id="O6" value="483" lower_limit="289" upper_limit="808"/>
                    <measurement group_id="O7" value="1982" lower_limit="929" upper_limit="4228"/>
                    <measurement group_id="O8" value="1478" lower_limit="756" upper_limit="2891"/>
                    <measurement group_id="O9" value="1028" lower_limit="445" upper_limit="2372"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2 at risk(N=28,40,35,17,26,26,11,14,9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2361" lower_limit="1743" upper_limit="3197"/>
                    <measurement group_id="O2" value="960" lower_limit="744" upper_limit="1237"/>
                    <measurement group_id="O3" value="763" lower_limit="582" upper_limit="1001"/>
                    <measurement group_id="O4" value="2517" lower_limit="1633" upper_limit="3881"/>
                    <measurement group_id="O5" value="820" lower_limit="578" upper_limit="1164"/>
                    <measurement group_id="O6" value="705" lower_limit="496" upper_limit="1000"/>
                    <measurement group_id="O7" value="2197" lower_limit="1514" upper_limit="3187"/>
                    <measurement group_id="O8" value="1286" lower_limit="925" upper_limit="1788"/>
                    <measurement group_id="O9" value="929" lower_limit="616" upper_limit="1399"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B at risk(N=28,40,35,17,26,26,11,14,9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="399" lower_limit="254" upper_limit="628"/>
                    <measurement group_id="O2" value="152" lower_limit="104" upper_limit="222"/>
                    <measurement group_id="O3" value="183" lower_limit="122" upper_limit="274"/>
                    <measurement group_id="O4" value="508" lower_limit="274" upper_limit="939"/>
                    <measurement group_id="O5" value="140" lower_limit="85" upper_limit="231"/>
                    <measurement group_id="O6" value="147" lower_limit="89" upper_limit="242"/>
                    <measurement group_id="O7" value="319" lower_limit="170" upper_limit="596"/>
                    <measurement group_id="O8" value="197" lower_limit="114" upper_limit="341"/>
                    <measurement group_id="O9" value="241" lower_limit="118" upper_limit="493"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>No risk subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Noninferiority was concluded if the lower limit of the 2-sided 97.6% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.</non_inferiority_desc>
            <param_type>GMT Ratio (H1N1 strain)</param_type>
            <param_value>2.29</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.91</ci_lower_limit>
            <ci_upper_limit>2.76</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>No risk subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Noninferiority was concluded if the lower limit of the 2-sided 97.6% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.</non_inferiority_desc>
            <param_type>GMT Ratio (H3N2 strain)</param_type>
            <param_value>1.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.35</ci_lower_limit>
            <ci_upper_limit>1.89</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>No risk subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Noninferiority was concluded if the lower limit of the 2-sided 97.6% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.</non_inferiority_desc>
            <param_type>GMT ratio (B strain)</param_type>
            <param_value>2.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.57</ci_lower_limit>
            <ci_upper_limit>3.31</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>At risk subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Noninferiority was concluded if the lower limit of the 2-sided 97.6% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.</non_inferiority_desc>
            <param_type>GMT ratio (H1N1 strain)</param_type>
            <param_value>1.53</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.6</ci_lower_limit>
            <ci_upper_limit>3.93</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>At risk subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Noninferiority was concluded if the lower limit of the 2-sided 97.6% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.</non_inferiority_desc>
            <param_type>GMT ratio (H3N2 strain)</param_type>
            <param_value>2.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.89</ci_lower_limit>
            <ci_upper_limit>4.61</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>At risk subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Noninferiority was concluded if the lower limit of the 2-sided 97.6% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.</non_inferiority_desc>
            <param_type>GMT ratio (B strain)</param_type>
            <param_value>2.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.34</ci_lower_limit>
            <ci_upper_limit>4.67</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>No risk subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Noninferiority was concluded if the lower limit of the 2-sided 97.6% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.</non_inferiority_desc>
            <param_type>GMT ratio (H1N1 strain)</param_type>
            <param_value>3.33</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.77</ci_lower_limit>
            <ci_upper_limit>4.01</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>No risk subjects</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Noninferiority was concluded if the lower limit of the 2-sided 97.6% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.</non_inferiority_desc>
            <param_type>GMT ratio (H3N2 strain)</param_type>
            <param_value>2.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.75</ci_lower_limit>
            <ci_upper_limit>2.45</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>No risk subjects</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Noninferiority was concluded if the lower limit of the 2-sided 97.6% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.</non_inferiority_desc>
            <param_type>GMT ratio (B strain)</param_type>
            <param_value>3.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.72</ci_lower_limit>
            <ci_upper_limit>3.49</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>At risk subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Noninferiority was concluded if the lower limit of the 2-sided 97.6% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.</non_inferiority_desc>
            <param_type>GMT ratio (H1N1 strain)</param_type>
            <param_value>1.71</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.65</ci_lower_limit>
            <ci_upper_limit>4.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>At risk subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Noninferiority was concluded if the lower limit of the 2-sided 97.6% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.</non_inferiority_desc>
            <param_type>GMT ratio (H3N2 strain)</param_type>
            <param_value>3.22</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.38</ci_lower_limit>
            <ci_upper_limit>7.51</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>At risk subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Noninferiority was concluded if the lower limit of the 2-sided 97.6% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.</non_inferiority_desc>
            <param_type>GMT ratio (B strain)</param_type>
            <param_value>2.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.1</ci_lower_limit>
            <ci_upper_limit>3.98</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>No risk subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was &gt; -10%.</non_inferiority_desc>
            <param_type>GMT ratio (H1N1 strain)</param_type>
            <param_value>2.59</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.1</ci_lower_limit>
            <ci_upper_limit>3.21</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>No risk subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was &gt; -10%.</non_inferiority_desc>
            <param_type>GMT ratio (H3N2 strain)</param_type>
            <param_value>2.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.71</ci_lower_limit>
            <ci_upper_limit>2.52</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>No risk subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was &gt; -10%.</non_inferiority_desc>
            <param_type>GMT ratio (B strain)</param_type>
            <param_value>3.73</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.22</ci_lower_limit>
            <ci_upper_limit>4.33</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>At risk subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was &gt; -10%.</non_inferiority_desc>
            <param_type>GMT ratio (H1N1 strain)</param_type>
            <param_value>1.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.45</ci_lower_limit>
            <ci_upper_limit>4.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>At risk subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was &gt; -10%.</non_inferiority_desc>
            <param_type>GMT ratio (H3N2 strain)</param_type>
            <param_value>2.86</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.94</ci_lower_limit>
            <ci_upper_limit>8.66</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>At risk subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was &gt; -10%.</non_inferiority_desc>
            <param_type>GMT ratio (B strain)</param_type>
            <param_value>1.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.45</ci_lower_limit>
            <ci_upper_limit>4.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>No risk subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was &gt; -10%.</non_inferiority_desc>
            <param_type>GMT ratio (H1N1 strain)</param_type>
            <param_value>3.67</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.97</ci_lower_limit>
            <ci_upper_limit>4.54</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>No risk subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was &gt; -10%.</non_inferiority_desc>
            <param_type>GMT ratio (H3N2 strain)</param_type>
            <param_value>2.78</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.29</ci_lower_limit>
            <ci_upper_limit>3.37</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>No risk subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was &gt; -10%.</non_inferiority_desc>
            <param_type>GMT ratio (B strain)</param_type>
            <param_value>4.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.46</ci_lower_limit>
            <ci_upper_limit>4.65</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>At risk subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the lower bound of confidence interval for day 50 vaccine group difference was &gt; -10%.</non_inferiority_desc>
            <param_type>GMT ratio (H1N1 strain)</param_type>
            <param_value>1.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.45</ci_lower_limit>
            <ci_upper_limit>4.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>At risk subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Noninferiority was concluded if the lower limit of the 2-sided 97.6% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.</non_inferiority_desc>
            <param_type>GMT ratio (H3N2 strain)</param_type>
            <param_value>4.32</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.43</ci_lower_limit>
            <ci_upper_limit>13</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>At risk subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Noninferiority was concluded if the lower limit of the 2-sided 97.6% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.</non_inferiority_desc>
            <param_type>GMT ratio (B strain)</param_type>
            <param_value>3.69</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.67</ci_lower_limit>
            <ci_upper_limit>8.15</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>No risk subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Noninferiority was concluded if the lower limit of the 2-sided 97.6% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.</non_inferiority_desc>
            <param_type>GMT ratio (H1N1 strain)</param_type>
            <param_value>1.35</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.89</ci_lower_limit>
            <ci_upper_limit>2.04</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>No risk subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Noninferiority was concluded if the lower limit of the 2-sided 97.6% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.</non_inferiority_desc>
            <param_type>GMT ratio (H3N2 strain)</param_type>
            <param_value>1.59</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.14</ci_lower_limit>
            <ci_upper_limit>2.22</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>No risk subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Noninferiority was concluded if the lower limit of the 2-sided 97.6% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.</non_inferiority_desc>
            <param_type>GMT ratio (B strain)</param_type>
            <param_value>1.68</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.3</ci_lower_limit>
            <ci_upper_limit>2.15</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>At risk subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Noninferiority was concluded if the lower limit of the 2-sided 97.6% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.</non_inferiority_desc>
            <param_type>GMT ratio (H1N1 strain)</param_type>
            <param_value>1.73</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.29</ci_lower_limit>
            <ci_upper_limit>10</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>At risk subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Noninferiority was concluded if the lower limit of the 2-sided 97.6% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.</non_inferiority_desc>
            <param_type>GMT ratio (H3N2 strain)</param_type>
            <param_value>1.16</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.33</ci_lower_limit>
            <ci_upper_limit>4.01</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>At risk subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Noninferiority was concluded if the lower limit of the 2-sided 97.6% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.</non_inferiority_desc>
            <param_type>GMT ratio (B strain)</param_type>
            <param_value>1.45</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.53</ci_lower_limit>
            <ci_upper_limit>3.94</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>No risk subjects</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Noninferiority was concluded if the lower limit of the 2-sided 97.6% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.</non_inferiority_desc>
            <param_type>GMT ratio (H1N1 strain)</param_type>
            <param_value>2.24</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.48</ci_lower_limit>
            <ci_upper_limit>3.39</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>No risk subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Noninferiority was concluded if the lower limit of the 2-sided 97.6% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.</non_inferiority_desc>
            <param_type>GMT ratio (H3N2 strain)</param_type>
            <param_value>1.76</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.26</ci_lower_limit>
            <ci_upper_limit>2.46</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>No risk subjects</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Noninferiority was concluded if the lower limit of the 2-sided 97.6% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.</non_inferiority_desc>
            <param_type>GMT ratio (B strain)</param_type>
            <param_value>1.59</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.24</ci_lower_limit>
            <ci_upper_limit>2.04</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>At risk subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Noninferiority was concluded if the lower limit of the 2-sided 97.6% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.</non_inferiority_desc>
            <param_type>GMT ratio (H1N1 strain)</param_type>
            <param_value>2.48</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.34</ci_lower_limit>
            <ci_upper_limit>18</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>At risk subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Noninferiority was concluded if the lower limit of the 2-sided 97.6% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.</non_inferiority_desc>
            <param_type>GMT ratio (H3N2 strain)</param_type>
            <param_value>1.98</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.49</ci_lower_limit>
            <ci_upper_limit>7.92</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>At risk subjects.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Noninferiority was concluded if the lower limit of the 2-sided 97.6% confidence interval of the postvaccination (day 50) ratio of GMTs was above 0.667.</non_inferiority_desc>
            <param_type>GMT ratio (B strain)</param_type>
            <param_value>0.71</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.23</ci_lower_limit>
            <ci_upper_limit>2.16</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The HI GMTs Against Heterologous Strains, by Vaccine Group (6 to &lt;72 Months Age Group)</title>
        <description>The HI antibody titers against the heterologous strains following vaccination with either aTIV, licensed comparator or TIV, at three weeks and at six months after vaccination are reported as GMTs.</description>
        <time_frame>Day 1, Day 50, Day 209</time_frame>
        <population>Analysis was done on the FAS Persistence</population>
        <group_list>
          <group group_id="O1">
            <title>aTIV (6 to &lt;72 Months)</title>
            <description>Subjects received an investigational MF59-adjuvanted trivalent influenza vaccine (aTIV), subjects aged between 6 to &lt;36 months received two doses of 0.25 mL each, while subjects aged ≥36 months received two doses of 0.5 mL each, at Days 1 &amp; 29</description>
          </group>
          <group group_id="O2">
            <title>Comparator TIV (6 to &lt;72 Months)</title>
            <description>Subjects received a licensed comparator trivalent split influenza vaccine (comparator TIV), subjects aged between 6 to &lt;36 months received two doses of 0.25 mL each, while subjects aged ≥36 months received two doses of 0.5 mL each, at Days 1 &amp; 29</description>
          </group>
          <group group_id="O3">
            <title>TIV (6 to &lt;72 Months)</title>
            <description>Subjects received an investigational trivalent split influenza vaccine (TIV), subjects aged between 6 to &lt;36 months received two doses of 0.25 mL each, while subjects aged ≥36 months received two doses of 0.5 mL each, at Days 1 &amp; 29</description>
          </group>
        </group_list>
        <measure>
          <title>The HI GMTs Against Heterologous Strains, by Vaccine Group (6 to &lt;72 Months Age Group)</title>
          <description>The HI antibody titers against the heterologous strains following vaccination with either aTIV, licensed comparator or TIV, at three weeks and at six months after vaccination are reported as GMTs.</description>
          <population>Analysis was done on the FAS Persistence</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="380"/>
                <count group_id="O2" value="445"/>
                <count group_id="O3" value="431"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1/Jersey - Day 1 (N=380,445,430)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" lower_limit="9.37" upper_limit="11"/>
                    <measurement group_id="O2" value="9.75" lower_limit="8.85" upper_limit="11"/>
                    <measurement group_id="O3" value="10" lower_limit="9.07" upper_limit="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H1N1/Jersey - Day 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51" lower_limit="45" upper_limit="58"/>
                    <measurement group_id="O2" value="29" lower_limit="26" upper_limit="33"/>
                    <measurement group_id="O3" value="31" lower_limit="27" upper_limit="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H1N1/Jersey - Day 209</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21" lower_limit="19" upper_limit="23"/>
                    <measurement group_id="O2" value="17" lower_limit="16" upper_limit="19"/>
                    <measurement group_id="O3" value="18" lower_limit="16" upper_limit="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2/Uruguay - Day 1 (N=380,445,430)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17" lower_limit="15" upper_limit="20"/>
                    <measurement group_id="O2" value="18" lower_limit="16" upper_limit="20"/>
                    <measurement group_id="O3" value="17" lower_limit="15" upper_limit="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2/Uruguay - Day 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="184" lower_limit="165" upper_limit="206"/>
                    <measurement group_id="O2" value="88" lower_limit="79" upper_limit="98"/>
                    <measurement group_id="O3" value="71" lower_limit="63" upper_limit="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2/Uruguay- Day 209</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42" lower_limit="37" upper_limit="47"/>
                    <measurement group_id="O2" value="31" lower_limit="28" upper_limit="34"/>
                    <measurement group_id="O3" value="27" lower_limit="24" upper_limit="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B strain - Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.98" lower_limit="5.72" upper_limit="6.25"/>
                    <measurement group_id="O2" value="5.8" lower_limit="5.55" upper_limit="6.05"/>
                    <measurement group_id="O3" value="5.85" lower_limit="5.6" upper_limit="6.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B strain - Day 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" lower_limit="89" upper_limit="111"/>
                    <measurement group_id="O2" value="34" lower_limit="31" upper_limit="38"/>
                    <measurement group_id="O3" value="35" lower_limit="31" upper_limit="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B strain Day 209</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20" lower_limit="18" upper_limit="22"/>
                    <measurement group_id="O2" value="11" lower_limit="9.86" upper_limit="12"/>
                    <measurement group_id="O3" value="11" lower_limit="9.94" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects Achieving Seroconversion or ≥4 Fold Increase in HI Titers, Against Heterologous Strains</title>
        <description>The percentage of subjects achieving seroconversion or ≥4 fold increase in HI titers from baseline, against heterologous strains, at three weeks and six months after last vaccination with aTIV or licensed comparator or TIV.</description>
        <time_frame>Day 50, Day 209</time_frame>
        <population>Subjects aged 6 through &lt;72 months of age - Full Analyses Set (FAS) Persistence</population>
        <group_list>
          <group group_id="O1">
            <title>aTIV (6 to &lt;72 Months)</title>
            <description>Subjects received an investigational MF59-adjuvanted trivalent influenza vaccine (aTIV), subjects aged between 6 to &lt;36 months received two doses of 0.25 mL each, while subjects aged ≥36 months received two doses of 0.5 mL each, at Days 1 &amp; 29</description>
          </group>
          <group group_id="O2">
            <title>Comparator TIV (6 to &lt;72 Months)</title>
            <description>Subjects received a licensed comparator trivalent split influenza vaccine (comparator TIV), subjects aged between 6 to &lt;36 months received two doses of 0.25 mL each, while subjects aged ≥36 months received two doses of 0.5 mL each, at Days 1 &amp; 29</description>
          </group>
          <group group_id="O3">
            <title>TIV (6 to &lt;72 Months)</title>
            <description>Subjects received an investigational trivalent split influenza vaccine (TIV), subjects aged between 6 to &lt;36 months received two doses of 0.25 mL each, while subjects aged ≥36 months received two doses of 0.5 mL each, at Days 1 &amp; 29</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Achieving Seroconversion or ≥4 Fold Increase in HI Titers, Against Heterologous Strains</title>
          <description>The percentage of subjects achieving seroconversion or ≥4 fold increase in HI titers from baseline, against heterologous strains, at three weeks and six months after last vaccination with aTIV or licensed comparator or TIV.</description>
          <population>Subjects aged 6 through &lt;72 months of age - Full Analyses Set (FAS) Persistence</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="380"/>
                <count group_id="O2" value="445"/>
                <count group_id="O3" value="431"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1/Jersey, Day 50 (N=380,445,430)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.16" lower_limit="48.00" upper_limit="58.26"/>
                    <measurement group_id="O2" value="36.85" lower_limit="32.36" upper_limit="41.52"/>
                    <measurement group_id="O3" value="36.05" lower_limit="31.50" upper_limit="40.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H1N1/Jersey, Day 209 (N=380,445,430)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.95" lower_limit="29.20" upper_limit="38.95"/>
                    <measurement group_id="O2" value="19.33" lower_limit="15.76" upper_limit="23.31"/>
                    <measurement group_id="O3" value="20.70" lower_limit="16.96" upper_limit="24.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2/Uruguay, Day 50 (N=380,445,430)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.84" lower_limit="88.62" upper_limit="94.39"/>
                    <measurement group_id="O2" value="60.9" lower_limit="56.19" upper_limit="65.46"/>
                    <measurement group_id="O3" value="53.26" lower_limit="48.42" upper_limit="58.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2/Uruguay, Day 209 (N=380,445,430)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.26" lower_limit="35.29" upper_limit="45.39"/>
                    <measurement group_id="O2" value="23.82" lower_limit="19.94" upper_limit="28.06"/>
                    <measurement group_id="O3" value="19.07" lower_limit="15.46" upper_limit="23.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B strain, Day 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.63" lower_limit="89.53" upper_limit="95.05"/>
                    <measurement group_id="O2" value="53.71" lower_limit="48.95" upper_limit="58.41"/>
                    <measurement group_id="O3" value="52.90" lower_limit="48.07" upper_limit="57.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B strain, Day 209</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.0" lower_limit="25.43" upper_limit="34.88"/>
                    <measurement group_id="O2" value="13.93" lower_limit="10.85" upper_limit="17.50"/>
                    <measurement group_id="O3" value="17.63" lower_limit="14.15" upper_limit="21.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparison of Antibody Responses of aTIV With TIV and Comparator TIV in Terms of GMTs Against Homologous Strains, After One Vaccination</title>
        <description>To demonstrate the GMTs at three weeks after one dose of aTIV are statistically significantly higher to the corresponding response's of comparator TIV and TIV.</description>
        <time_frame>Day 1, Day 29</time_frame>
        <population>Analysis was done on the FAS (Persistence).</population>
        <group_list>
          <group group_id="O1">
            <title>aTIV (6 to &lt;72 Months)</title>
            <description>Subjects received an investigational MF59-adjuvanted trivalent influenza vaccine (aTIV), subjects aged between 6 to &lt;36 months received two doses of 0.25 mL each, while subjects aged ≥36 months received two doses of 0.5 mL each, at Days 1 &amp; 29</description>
          </group>
          <group group_id="O2">
            <title>Comparator TIV (6 to &lt;72 Months)</title>
            <description>Subjects received a licensed comparator trivalent split influenza vaccine (comparator TIV), subjects aged between 6 to &lt;36 months received two doses of 0.25 mL each, while subjects aged ≥36 months received two doses of 0.5 mL each, at Days 1 &amp; 29</description>
          </group>
          <group group_id="O3">
            <title>TIV (6 to &lt;72 Months)</title>
            <description>Subjects received an investigational trivalent split influenza vaccine (TIV), subjects aged between 6 to &lt;36 months received two doses of 0.25 mL each, while subjects aged ≥36 months received two doses of 0.5 mL each, at Days 1 &amp; 29</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of Antibody Responses of aTIV With TIV and Comparator TIV in Terms of GMTs Against Homologous Strains, After One Vaccination</title>
          <description>To demonstrate the GMTs at three weeks after one dose of aTIV are statistically significantly higher to the corresponding response's of comparator TIV and TIV.</description>
          <population>Analysis was done on the FAS (Persistence).</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="715"/>
                <count group_id="O2" value="822"/>
                <count group_id="O3" value="820"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1- Day 1 (N=714,822,820)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28" lower_limit="24" upper_limit="32"/>
                    <measurement group_id="O2" value="24" lower_limit="20" upper_limit="27"/>
                    <measurement group_id="O3" value="27" lower_limit="23" upper_limit="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H1N1- Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="647" lower_limit="562" upper_limit="745"/>
                    <measurement group_id="O2" value="159" lower_limit="139" upper_limit="182"/>
                    <measurement group_id="O3" value="170" lower_limit="148" upper_limit="194"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2 - Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42" lower_limit="36" upper_limit="48"/>
                    <measurement group_id="O2" value="43" lower_limit="37" upper_limit="49"/>
                    <measurement group_id="O3" value="43" lower_limit="38" upper_limit="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2 - Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1087" lower_limit="1004" upper_limit="1176"/>
                    <measurement group_id="O2" value="558" lower_limit="517" upper_limit="602"/>
                    <measurement group_id="O3" value="453" lower_limit="420" upper_limit="490"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B strain Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" lower_limit="9.29" upper_limit="11"/>
                    <measurement group_id="O2" value="10" lower_limit="9.57" upper_limit="11"/>
                    <measurement group_id="O3" value="10" lower_limit="9.34" upper_limit="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B strain Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="119" lower_limit="106" upper_limit="134"/>
                    <measurement group_id="O2" value="58" lower_limit="52" upper_limit="65"/>
                    <measurement group_id="O3" value="61" lower_limit="54" upper_limit="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>GMTs were considered to be statistically significantly higher if the lower bound of the 95% confidence interval around the vaccine group ratio was &gt;1.0</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMT ratio (H1N1 strain)</param_type>
            <param_value>4.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.34</ci_lower_limit>
            <ci_upper_limit>4.95</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>statistically significantly greater response was concluded if the lower bound of the 95% confidence interval around the vaccine group ratio is &gt;1.0</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMT ratio (H3N2 strain)</param_type>
            <param_value>1.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.74</ci_lower_limit>
            <ci_upper_limit>2.18</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>statistically significantly greater response was concluded if the lower bound of the 95% CI around the vaccine group ratio was &gt;1.0</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMT ratio (B strain)</param_type>
            <param_value>2.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.73</ci_lower_limit>
            <ci_upper_limit>2.39</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>statistically significantly greater response was concluded if the lower bound of the 95% CI around the vaccine group ratio was &gt;1.0</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMT ratio (H1N1 strain)</param_type>
            <param_value>3.82</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>3.14</ci_lower_limit>
            <ci_upper_limit>4.64</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>statistically significantly greater response was concluded if the lower bound of the 95% CI around the vaccine group ratio was &gt;1.0</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMT ratio (H3N2 strain)</param_type>
            <param_value>2.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.15</ci_lower_limit>
            <ci_upper_limit>2.68</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>statistically significantly greater response was concluded if the lower bound of the 95% CI around the vaccine group ratio was &gt;1.0</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMT ratio (B strain)</param_type>
            <param_value>1.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.65</ci_lower_limit>
            <ci_upper_limit>2.29</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Solicited Adverse Events After Vaccination</title>
        <description>The number of subjects reporting any solicited local and systemic adverse events (AEs), following vaccination with aTIV or licensed comparator or TIV.</description>
        <time_frame>Day 1 through Day 7 after any vaccination</time_frame>
        <population>Analysis was done on solicited safety set i.e all subjects who had received at least one study vaccine and had provided data on post vaccination solicited AEs</population>
        <group_list>
          <group group_id="O1">
            <title>aTIV (6 to &lt;72 Months)</title>
            <description>Subjects received an investigational MF59-adjuvanted trivalent influenza vaccine (aTIV), subjects aged between 6 to &lt;36 months received two doses of 0.25 mL each, while subjects aged ≥36 months received two doses of 0.5 mL each, at Days 1 &amp; 29</description>
          </group>
          <group group_id="O2">
            <title>TIV (6 to &lt;72 Months)</title>
            <description>Subjects received an investigational trivalent split influenza vaccine (TIV), subjects aged between 6 to &lt;36 months received two doses of 0.25 mL each, while subjects aged ≥36 months received two doses of 0.5 mL each, at Days 1 &amp; 29</description>
          </group>
          <group group_id="O3">
            <title>Comparator TIV (6 to &lt;72 Months)</title>
            <description>Subjects received a licensed comparator trivalent split influenza vaccine (comparator TIV), subjects aged between 6 to &lt;36 months received two doses of 0.25 mL each, while subjects aged ≥36 months received two doses of 0.5 mL each, at Days 1 &amp; 29</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Solicited Adverse Events After Vaccination</title>
          <description>The number of subjects reporting any solicited local and systemic adverse events (AEs), following vaccination with aTIV or licensed comparator or TIV.</description>
          <population>Analysis was done on solicited safety set i.e all subjects who had received at least one study vaccine and had provided data on post vaccination solicited AEs</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3082"/>
                <count group_id="O2" value="1453"/>
                <count group_id="O3" value="1451"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any local</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1082"/>
                    <measurement group_id="O2" value="292"/>
                    <measurement group_id="O3" value="311"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site ecchymosis(N=3075,1450,1446)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="191"/>
                    <measurement group_id="O2" value="72"/>
                    <measurement group_id="O3" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site erythema (N=3075,1450,1446)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="312"/>
                    <measurement group_id="O2" value="109"/>
                    <measurement group_id="O3" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site induration (N=3075,1450,1446)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="258"/>
                    <measurement group_id="O2" value="62"/>
                    <measurement group_id="O3" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site tenderness (N=1495,1025,1012)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="152"/>
                    <measurement group_id="O2" value="70"/>
                    <measurement group_id="O3" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site swelling (N=3075,1450,1446)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="217"/>
                    <measurement group_id="O2" value="1450"/>
                    <measurement group_id="O3" value="1446"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site pain (N=1580,422,429)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1580"/>
                    <measurement group_id="O2" value="422"/>
                    <measurement group_id="O3" value="429"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any systemic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1487"/>
                    <measurement group_id="O2" value="604"/>
                    <measurement group_id="O3" value="569"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>chills (N=1578,423,428)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="154"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia (N=1578,423,429)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="216"/>
                    <measurement group_id="O2" value="43"/>
                    <measurement group_id="O3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arthralgia (N=1578,423,429)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="125"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache (N=1578,423,429)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="282"/>
                    <measurement group_id="O2" value="46"/>
                    <measurement group_id="O3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue (N=1578,423,430)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="204"/>
                    <measurement group_id="O2" value="43"/>
                    <measurement group_id="O3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eating Habit (N=3076,1450,1446)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="437"/>
                    <measurement group_id="O2" value="196"/>
                    <measurement group_id="O3" value="205"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea (N=3075,1450,1447)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="423"/>
                    <measurement group_id="O2" value="231"/>
                    <measurement group_id="O3" value="220"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability (N=1496,1024,1013)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="290"/>
                    <measurement group_id="O2" value="164"/>
                    <measurement group_id="O3" value="190"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Crying (N=1463,1001,990)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="186"/>
                    <measurement group_id="O2" value="105"/>
                    <measurement group_id="O3" value="122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleepiness (N=1495,1024,1012)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="229"/>
                    <measurement group_id="O2" value="150"/>
                    <measurement group_id="O3" value="153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting (N=3075,1451,1446)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="249"/>
                    <measurement group_id="O2" value="100"/>
                    <measurement group_id="O3" value="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever (≥38°C) (N=3074,1450,1446)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="748"/>
                    <measurement group_id="O2" value="236"/>
                    <measurement group_id="O3" value="224"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1047"/>
                    <measurement group_id="O2" value="310"/>
                    <measurement group_id="O3" value="317"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Axillary Temperature (≥40°C) (N=3074,1450,1446)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Analgesic Antipyretic Med. used(N=3076,1448,1444)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="984"/>
                    <measurement group_id="O2" value="285"/>
                    <measurement group_id="O3" value="282"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Unsolicited Adverse Events After Vaccination</title>
        <description>The number of subjects reporting any unsolicited adverse events (AEs) between Day 1 to Day 50, serious adverse events (SAEs), AE leading to withdrawal (WD), new onset of chronic disease(NOCD), adverse events of special interest following vaccination with aTIV or licensed comparator or TIV throughout the study (Day 1 to Day 394).</description>
        <time_frame>Day 1 to Day 394</time_frame>
        <population>Analysis was done on the safety population i.e all subjects who had received at least one study vaccine and had postvaccination safety data</population>
        <group_list>
          <group group_id="O1">
            <title>aTIV (6 to &lt;72 Months)</title>
            <description>Subjects received an investigational MF59-adjuvanted trivalent influenza vaccine (aTIV), subjects aged between 6 to &lt;36 months received two doses of 0.25 mL each, while subjects aged ≥36 months received two doses of 0.5 mL each, at Days 1 &amp; 29</description>
          </group>
          <group group_id="O2">
            <title>Comparator TIV (6 to &lt;72 Months)</title>
            <description>Subjects received a licensed comparator trivalent split influenza vaccine (comparator TIV), subjects aged between 6 to &lt;36 months received two doses of 0.25 mL each, while subjects aged ≥36 months received two doses of 0.5 mL each, at Days 1 &amp; 29</description>
          </group>
          <group group_id="O3">
            <title>TIV (6 to &lt;72 Months)</title>
            <description>Subjects received an investigational trivalent split influenza vaccine (TIV), subjects aged between 6 to &lt;36 months received two doses of 0.25 mL each, while subjects aged ≥36 months received two doses of 0.5 mL each, at Days 1 &amp; 29</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Unsolicited Adverse Events After Vaccination</title>
          <description>The number of subjects reporting any unsolicited adverse events (AEs) between Day 1 to Day 50, serious adverse events (SAEs), AE leading to withdrawal (WD), new onset of chronic disease(NOCD), adverse events of special interest following vaccination with aTIV or licensed comparator or TIV throughout the study (Day 1 to Day 394).</description>
          <population>Analysis was done on the safety population i.e all subjects who had received at least one study vaccine and had postvaccination safety data</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3123"/>
                <count group_id="O2" value="1474"/>
                <count group_id="O3" value="1477"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AEs (Day 1 to Day 50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1541"/>
                    <measurement group_id="O2" value="859"/>
                    <measurement group_id="O3" value="808"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Possibly/probably related AEs(Day 1 to Day 50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="158"/>
                    <measurement group_id="O2" value="101"/>
                    <measurement group_id="O3" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115"/>
                    <measurement group_id="O2" value="64"/>
                    <measurement group_id="O3" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Possibly/probably related SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AE leading to WD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NOCD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="31"/>
                    <measurement group_id="O3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AESI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Deaths</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Solicited AEs collected from Day 1-7 after each vaccination, Unsolicited AEs, Adverse Events of Special Interest, New onset chronic disease, AEs leading to withdrawal and serious adverse events reported for through out the study (Day 1-Day 394)</time_frame>
      <desc>Analysis was done on Full Safety Set - Subjects who received at least one study vaccination and provided post baseline safety data.</desc>
      <group_list>
        <group group_id="E1">
          <title>ATIV (6 to &lt;72 Months)</title>
          <description>Subjects received an investigational MF59-adjuvanted trivalent influenza vaccine (aTIV), subjects aged between 6 to &lt;36 months received two doses of 0.25 mL each, while subjects aged ≥36 months received two doses of 0.5 mL each, at Days 1 &amp; 29</description>
        </group>
        <group group_id="E2">
          <title>TIV (6 to &lt;72 Months)</title>
          <description>Subjects received an investigational trivalent split influenza vaccine (TIV), subjects aged between 6 to &lt;36 months received two doses of 0.25 mL each, while subjects aged ≥36 months received two doses of 0.5 mL each, at Days 1 &amp; 29</description>
        </group>
        <group group_id="E3">
          <title>Comparator TIV (6 to &lt;72 Months)</title>
          <description>Subjects received a licensed comparator trivalent split influenza vaccine (comparator TIV), subjects aged between 6 to &lt;36 months received two doses of 0.25 mL each, while subjects aged ≥36 months received two doses of 0.5 mL each, at Days 1 &amp; 29</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="115" subjects_at_risk="3123"/>
                <counts group_id="E2" subjects_affected="69" subjects_at_risk="1477"/>
                <counts group_id="E3" subjects_affected="64" subjects_at_risk="1474"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Coeliac Disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1474"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1477"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1474"/>
              </event>
              <event>
                <sub_title>Upper Gastrointestinal Disorder Hamorrage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1477"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1474"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Drowning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1477"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1474"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Type III Immune Complex Mediated Reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1474"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1474"/>
              </event>
              <event>
                <sub_title>Abscess Limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1474"/>
              </event>
              <event>
                <sub_title>Abscess Neck</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1474"/>
              </event>
              <event>
                <sub_title>Amoebiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1474"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1477"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1474"/>
              </event>
              <event>
                <sub_title>Arthritis Bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1477"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1474"/>
              </event>
              <event>
                <sub_title>Bacterial Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1474"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1477"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1474"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3123"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1477"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="1474"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1477"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1474"/>
              </event>
              <event>
                <sub_title>Dengue Fever</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="3123"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="1477"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1474"/>
              </event>
              <event>
                <sub_title>Diarrhoea Infectious</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1477"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1474"/>
              </event>
              <event>
                <sub_title>Dysentery</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1477"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1474"/>
              </event>
              <event>
                <sub_title>Encephalitis Viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1474"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="3123"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="1477"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="1474"/>
              </event>
              <event>
                <sub_title>Hepatitis A</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1477"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1474"/>
              </event>
              <event>
                <sub_title>Lower Respiratory Tract Infection Viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1474"/>
              </event>
              <event>
                <sub_title>Mastoiditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1474"/>
              </event>
              <event>
                <sub_title>Measles</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1474"/>
              </event>
              <event>
                <sub_title>Meningitis Pneumococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1477"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1474"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1474"/>
              </event>
              <event>
                <sub_title>Otitis Media</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1474"/>
              </event>
              <event>
                <sub_title>Otitis Media Bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1474"/>
              </event>
              <event>
                <sub_title>Otitis Media Chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1474"/>
              </event>
              <event>
                <sub_title>Parasitic Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1477"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1474"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1474"/>
              </event>
              <event>
                <sub_title>Pharyngotonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1477"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1474"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="3123"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="1477"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="1474"/>
              </event>
              <event>
                <sub_title>Pneumonia Bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1474"/>
              </event>
              <event>
                <sub_title>Pneumonia Viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1477"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1474"/>
              </event>
              <event>
                <sub_title>Pyelonephritis Acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1474"/>
              </event>
              <event>
                <sub_title>Respiratory Syncytial Virus Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1477"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1474"/>
              </event>
              <event>
                <sub_title>Respiratory Tract Infection Viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1474"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1477"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1474"/>
              </event>
              <event>
                <sub_title>Septic Shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1474"/>
              </event>
              <event>
                <sub_title>Shigella Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1477"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1474"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1474"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1474"/>
              </event>
              <event>
                <sub_title>Tooth Abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1474"/>
              </event>
              <event>
                <sub_title>Thypoid Fever</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1474"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1474"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1477"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1474"/>
              </event>
              <event>
                <sub_title>Varicella</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1474"/>
              </event>
              <event>
                <sub_title>Viral Infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1477"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1474"/>
              </event>
              <event>
                <sub_title>Viral Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1474"/>
              </event>
              <event>
                <sub_title>Roseola</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1474"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental Exposure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1474"/>
              </event>
              <event>
                <sub_title>Animal Bite</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="3123"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="1477"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="1474"/>
              </event>
              <event>
                <sub_title>Animal Scratch</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1474"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1474"/>
              </event>
              <event>
                <sub_title>Craniocerebral Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1474"/>
              </event>
              <event>
                <sub_title>Eye Injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1474"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1474"/>
              </event>
              <event>
                <sub_title>Femur Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1474"/>
              </event>
              <event>
                <sub_title>Forearm Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1477"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1474"/>
              </event>
              <event>
                <sub_title>Head Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1477"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1474"/>
              </event>
              <event>
                <sub_title>Humerus Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1474"/>
              </event>
              <event>
                <sub_title>Multiple Injuries</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1474"/>
              </event>
              <event>
                <sub_title>Radius Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1474"/>
              </event>
              <event>
                <sub_title>Road Traffic Accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1474"/>
              </event>
              <event>
                <sub_title>Skull Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1474"/>
              </event>
              <event>
                <sub_title>Subdural Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1474"/>
              </event>
              <event>
                <sub_title>Thermal Burn</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1474"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1474"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1477"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1474"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1474"/>
              </event>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1474"/>
              </event>
              <event>
                <sub_title>Metabolic Acidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1474"/>
              </event>
              <event>
                <sub_title>Tetany</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1477"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1474"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Acute Lymphocytic Leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1474"/>
              </event>
              <event>
                <sub_title>Cholesteatoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1474"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1474"/>
              </event>
              <event>
                <sub_title>Febrile Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="3123"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1477"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1474"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Adenoidal Hypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1474"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3123"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1477"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1474"/>
              </event>
              <event>
                <sub_title>Asthmatic Crisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1477"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1474"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1474"/>
              </event>
              <event>
                <sub_title>Bronchial Hyperreactivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1474"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1474"/>
              </event>
              <event>
                <sub_title>Tonsillary Hypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1474"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis Allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1477"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1474"/>
              </event>
              <event>
                <sub_title>Swelling Face</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1474"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Finger Amputation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1477"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1474"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2106" subjects_at_risk="3123"/>
                <counts group_id="E2" subjects_affected="905" subjects_at_risk="1477"/>
                <counts group_id="E3" subjects_affected="917" subjects_at_risk="1474"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="445" subjects_at_risk="3123"/>
                <counts group_id="E2" subjects_affected="247" subjects_at_risk="1477"/>
                <counts group_id="E3" subjects_affected="231" subjects_at_risk="1474"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="257" subjects_at_risk="3123"/>
                <counts group_id="E2" subjects_affected="107" subjects_at_risk="1477"/>
                <counts group_id="E3" subjects_affected="109" subjects_at_risk="1474"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Crying</sub_title>
                <counts group_id="E1" subjects_affected="186" subjects_at_risk="3123"/>
                <counts group_id="E2" subjects_affected="105" subjects_at_risk="1477"/>
                <counts group_id="E3" subjects_affected="124" subjects_at_risk="1474"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="204" subjects_at_risk="3123"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="1477"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="1474"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="312" subjects_at_risk="3123"/>
                <counts group_id="E2" subjects_affected="109" subjects_at_risk="1477"/>
                <counts group_id="E3" subjects_affected="102" subjects_at_risk="1474"/>
              </event>
              <event>
                <sub_title>Injection site hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="191" subjects_at_risk="3123"/>
                <counts group_id="E2" subjects_affected="72" subjects_at_risk="1477"/>
                <counts group_id="E3" subjects_affected="86" subjects_at_risk="1474"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <counts group_id="E1" subjects_affected="258" subjects_at_risk="3123"/>
                <counts group_id="E2" subjects_affected="62" subjects_at_risk="1477"/>
                <counts group_id="E3" subjects_affected="67" subjects_at_risk="1474"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="851" subjects_at_risk="3123"/>
                <counts group_id="E2" subjects_affected="177" subjects_at_risk="1477"/>
                <counts group_id="E3" subjects_affected="189" subjects_at_risk="1474"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" subjects_affected="217" subjects_at_risk="3123"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="1477"/>
                <counts group_id="E3" subjects_affected="43" subjects_at_risk="1474"/>
              </event>
              <event>
                <sub_title>Irritability postvaccinal</sub_title>
                <counts group_id="E1" subjects_affected="290" subjects_at_risk="3123"/>
                <counts group_id="E2" subjects_affected="165" subjects_at_risk="1477"/>
                <counts group_id="E3" subjects_affected="191" subjects_at_risk="1474"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="795" subjects_at_risk="3123"/>
                <counts group_id="E2" subjects_affected="279" subjects_at_risk="1477"/>
                <counts group_id="E3" subjects_affected="260" subjects_at_risk="1474"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="112" subjects_at_risk="3123"/>
                <counts group_id="E2" subjects_affected="70" subjects_at_risk="1477"/>
                <counts group_id="E3" subjects_affected="84" subjects_at_risk="1474"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="291" subjects_at_risk="3123"/>
                <counts group_id="E2" subjects_affected="151" subjects_at_risk="1477"/>
                <counts group_id="E3" subjects_affected="175" subjects_at_risk="1474"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="452" subjects_at_risk="3123"/>
                <counts group_id="E2" subjects_affected="237" subjects_at_risk="1477"/>
                <counts group_id="E3" subjects_affected="246" subjects_at_risk="1474"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="437" subjects_at_risk="3123"/>
                <counts group_id="E2" subjects_affected="197" subjects_at_risk="1477"/>
                <counts group_id="E3" subjects_affected="206" subjects_at_risk="1474"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="216" subjects_at_risk="3123"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="1477"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="1474"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="286" subjects_at_risk="3123"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="1477"/>
                <counts group_id="E3" subjects_affected="40" subjects_at_risk="1474"/>
              </event>
              <event>
                <sub_title>Hypersomnia</sub_title>
                <counts group_id="E1" subjects_affected="229" subjects_at_risk="3123"/>
                <counts group_id="E2" subjects_affected="150" subjects_at_risk="1477"/>
                <counts group_id="E3" subjects_affected="153" subjects_at_risk="1474"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Posting Director</name_or_title>
      <organization>Novartis Vaccines and Diagnostics</organization>
      <email>RegistryContactVaccinesUS@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

